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I. Introduction. 
It is one of the mysteries of medical history 
that acute myocardial infarction, with its dramatic 
symptoms and its gross and obvious pathological 
lesions, was not established as a clinical entity 
until as late as 1910. Accurate pathological ac- 
:counts had been given many years before (Weigert 1880, 
Cohnheim 1881, Huber 1882), the clinical features 
had been clearly described (H u chard. 1890) but path - 
:ology and symptoms had not been wedded in a systemat. 
:ic account of the condition as an entity quite dis- 
:tinct from angina pectoris, until the publication of 
a paper by Cbrastzow and Straschesko (1910). They 
described three cases, two of which they had diagnos 
in life, and emphasised many of the clinical features 
which are now common knowledge. Their report did 
not arouse much interest but in 1912 there appeared 
a noteworthy paper by Herrick which stressed the 
complexity and variability of the clinical features 
of cardiac infarction and, in particular, pointed out 
that all cases were not fatal. This article earned 
more conviction and further papers by Herrick (1918) 
were followed quickly by the appearance of an extens- 
:ive American literature. Out of many authors, 
Levine & Tranter (1918), Libman (1919), Pardee (1920), 
Robinson and lermann (1921) , Longcope (1922) , Wearn 
(1923), Gordinier (1924) and Faulkner, Marble & White 
(1924) may be mentioned as having each added some 
detail/ 
2. 
detail to the final and deinitive clinical picture 
which eventually emerged and which was convincingly 
presented in an excellent review by Hamman (1926). 
British physicians appear to have been slow to 
accept the reality of cardiac infarction as an entity 
distinct from angina pectoris. Mackenzie in 1923 
failed to make the distinction in his monograph on 
angina pectoris. However, McNee (1925) described the 
clinical picture in a study of 3 cases of coronary 
thrombosis and the report by Parkinson and Bedford 
(1928) of a clinical series of 100 and a post -mortem 
series of 83 is an indication that they had been aware¡ 
of the condition for some years. The delay in 
acceptance of coronary thrombosis as an entity is 
.indicated by the fact that it was not included until 
1930 in the International List of Causes of Death and 
in the Registrar -General's Report. 
Greater familiarity with the clinical picture 
on the part of physicians and progressive improvements 
in diagnostic methods, notably in electrocardiography, 
have naturally led to progressive increase in the 
reported incidence of coronary thrombosis in hospital 
admissions, and also to progressive increase in the 
.number of deaths due to disease of the coronary 
arteries noted in the Registrar -General's Report. 
Pathological studies, Meakins & Eakin (1932) have not 
shown any increase in the incidence of coronary 
thrombosis in routine autopsies carried out over 
comparable/ 
3. 
comparable five -year periods. However, Master (1947) 
in a convincing paper has inferred from an analysis 
of United States Census reports and from the sampling 
of death certificates that there is an undoubted in- 
:crease in the prevalence of coronary artery disease 
and more particularly of acute coronary occlusion. 
He calculates that every year at least 1 man in 50, 
140 years of age and over, and 1 woman in 150 in the 
same age group, sustain closure of a coronary artery. 
He attributes the increasing incidence to (1) lengthen - 
:ed span of life, (2) ageing of the population, (3) 
improved diagnosis and treatment, and. (4) accuracy 
in terminology. 
Improved diagnosis by leading to earlier recog- 
:nition and treatment has brought about some improve - 
:ment in mortality rate. But the disease has lacked 
any specific therapy. It is known that if the first 
month is survived then the prognosis progressively 
improves (Bland 83 White 1941). Causes of death in 
the first month are:- (1) Acute circulatory failure 
from the massivity of the original infarct. (2) Con- 
:gestive heart failure from severe myocardial damage - 
often due to repeated episodes in different branches 
of the coronary tree. (3) Cardiac rupture. (4) Heart - 
block and other arrhythmias. (5) Thrombo- embolic com- 
:plications. 
It has frecauently been noted that what appears 
vo/ 
,{ ..t .+: t, dt^VFl4fl . 
4. 
to be a satisfactory recovery from myocardial infarc- 
:tion may be suddenly marred by a second episode or 
by some other thrombo- embolic process which may 
result in death or permanent invalidism. The 
realisation of the importance of such complications 
in this condition and the remarkable success achieved 
with the use of the anticoagulants heparin and 
dicumarol in the treatment of post -operative and 
puerperal throxlbo- phlebitis and pulmonary embolism, 
has led to the trial of these substances in cases of 
myocardial infarction. 
This disease frequently strikes doom men in the 
most productive years of life who have great profes- 
:sional and family responsibilities - men whom the 
world can ill spare. line of treatment which 
offers a hope of a lessened mortality is worth the 
most serious scrutiny and evaluation. 
In this paper an attempt will be made to elucid- 
:ate and define the pathological justification for 
lessening the coagulability of the blood (Part II), 
the methods available will be discussed (III), the 
reported results of other workers will be reviewed (IV) 
and the author's experience in a short clinical 
series will be presented (V) . After a brief critical 
consideration. of a form of therapy directly contrary 
in rationale to the subject of this paper (VI.), the 
author's conclusions will be embodied in a final di; - 
:cussion (VII.) and summary (VIII.) 
5. 
II. Thrombo- embolic complications of myocardial 
infarction. 
(a) Incidence, severity and significance. 
That coronary thrombosis is frequently complicat- 
:ed by thrombo- embolic phenomena has long been recog- 
Ì 
:nised. Various observers in both clinical and path - 
:ological studies have recorded, in varying incidence, 
the occurrence of the following conditions subsequent 
to or accompanying an episode of acute myocardial 
infarction: 
(1) The presence of mural thrombi in the heart 
chambers. 
(2) The onset of sudden occlusion of systemic arteries 
in the extremities, brain, kidney, spleen, 
mesentery or aorta. 
(3) Peripheral phlebothrombosis - notably in the calf 
veins. 
(4) The appearance of pulmonary infarction as a con - 
:sequence of (1) or (3). 
(5) Development of a secondary coronary thrombosis 
in a previously uninvolved branch of the coronary 
tree. 
The existence of mural thrombi can be only a 
matter of surmise during life. sudden arterial 
occlusion is not necessaril- due to an embolus 
detached from a mural thrombus, since pathological 
studies/ 
6. 
studies have shown that such occlusions may occur in 
cases which show no evidence of thrombi within the 
heart chambers at post mortem. Hellerstein & Martin 
(1947) in an autopsy series of 160 cases of recent 
and remote myocardial infarction found mural thrombi 
in 65. Though 36 of these showed arterial occlusions, 
yet 37 of the 95 cases free of mural thrombi showed 
similar lesions. It is clear then that the incid- 
:ence of mural thrombi cannot be estimated in a 
clinical series but only in post -mortem material. It' 
is of interest that such experienced observers as Wolff 
and White (1926) state that a mural thrombus always 
occurs in myocardial infarction though they found such, 
in only 300 of their post -mortem cases. 
Table I. records the incidence of mural thrombi found 
at autopsy by a number of different observers. 
Table I. Incidence of mural thrombi found at autopsy 
in cases of myocardial infarction. 
Author. No. of Cases with 
autopsies. mural thrombi. 
Wolff & White (1926) 23 7 
Parkinson & Bedford (1928) 83 14 
Levine & Brown (1929) 46 38 
Lisa & Ring (1932) 100 34 
Meakins & Bakin (1932) 62 29 
Appelbaum & Nicholson (1935) 150 81 
Bean (1938) 300 142 
Garvin (1941) 133 89 
Nay & Barnes (1945) 11 7 
Hellerstein & Martin (1947) 160 65 
Totals 1068 506 a 470 
Though/ 
7. 
Though these figures conclusively show that 
almost half of subjects dying from myocardial infarc- 
:tion have mural thrombi in the heart chambers, it 
must be remembered that post -mortem series represent 
the most severe cases and are not necessarily typical 
of the usual pathology in non -fatal cases. Further - 
:more, it has been shown that the incidence of mural 
thrombi is high in cases dying from other forms of 
heart disease. Garvin (1941) in a study of 771 deaths 
from heart disease found mural thrombi in 35.1, of 
cases of coronary disease without infarction, in 31.9; :, 
of cases of rheumatic heart disease and in 3l.3áh of 
cases of hypertensive heart disease. However, Garvin 
points out that congestive heart failure which pre- 
:disposes to mural thrombi was almost always present 
in the last 3 groups but complicated the fatal cases 
of myocardial infarction in a much smaller percentage. 
This fact increases the significance of the greater 
incidence of mural thrombi in fatal cases of myocardial 
infarction and suggests there is a much greater 
thrombosing tendency in this condition. 
That systemic arterial occlusion embolic or thrombotic 
frequently complicates convalescence from myocardial 
infarction has been shown by many observers. Table 
II. lists the recorded post -mortem incidence of such 



























































































































































































































































































































































































































































































































































































There is considerable discrepancy between the 
figures recorded in the various series above and it is 
clear from the original papers that some observers 
have not made a special search for infarcts in parti- 
':cular sites such as brain and viscera. The true 
incidence is probably higher than 39.616, and is better 
reflected in the carefully analysed series of Meakins 
and Eakin (1932) and Garvin (1942) noted in Table II. 
which give an incidence of 631=,. 
Pulmonary infarction is a well recognised 
complication of coronary thrombosis. Whether the 
source of the embolus is more commonly the right side; 
of the heart or the peripheral veins, cannot be 
stated with certainty. In the experience of be. 
(1938) 75 of patients with right ventricular thrombi 
had pulmonary emboli, but he found that massive emboli 
occluding the lumen of the pulmonary artery were 
always derived from the systemic veins. Woods and 
Barnes (1941) found that the iliac veins were the 
source of the emboli in all their fatal cases of 
pulmonary infarction. The incidence recorded in the 
literature is listed in Table III. 
Table III. Incidence of pulmonary infarction found 
at autopsy in cases of myocardial infarction. 
authors/ 
9. 
Authors. No. of 
autopsies. 
No. of pulmonary 
infarctions. 
yarkinson & Bedford (1928) 83. 7 
Meakins & Eakin (1932) 62 47 
Kugel & I,ichtman (1933) 95 33 
saphir et al. (1935) 34 10 
Bean (1938) 300 43 
Eppinger & Kennedy (1938) 200 46 
Woods & Barnes (1941) 60 6 
Garvin (1942) 133 45 
Ñay & Barnes (1945) 11 6 
Hellerstein & Martin (1947) 160 33 
1138 276 s 24 
Tables I.,II. & III. amply illustrate the 
frequency of thrombo- embolic phenomena in deaths from 
myocardial infarction. It may be objected that such 
er 
phenomena are also found, though in a small/ percentage 
(Garvin 1941 & 1942), in patients dead from other 
froms of heart disease. While this is true it is 
emphasised that thrombo- emboli frequently mar what 
appears to be satisfactory recovery from myocardial 
infarction, whereas in other types of heart disease 
such manifestations (except in subacute bacterial 
endocarditis and auricular fibrillation) are more 
commonly terminal complications of congestive heart 
failure. 
12he significance of thrombosis and embolism in myo- 
:cardial infarction can perhaps be better appreciated 
by studies of clinical material (Table IV.) and by 
a consideration of their importance as the chief cause 
of death. 
Table IV. Incidence of thrombo- embolic complications' 
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Howard 0_934) 165 17 
Hyman & Parsonnet (1932) 51 17 - 11.40 
Conner & Holt (1930) 287 42 
Levine (1929) 145 17 
Blumer (1937) 175 27 
Master et al (1939) 500 29 
Woods & Barnes (1941) 128 19 
Nay & Barnes (1945) 100 37 1945 -48 
Peters et al. (1946) 





Greisman & Marcus (1948) 100 21 
Wright et al. (1948) 368 92 
Totals 2245 367 = 16.30 
A striking feature of the figures noted in Table 
IV. is the very marked increase in thrombo -embolic 
complications which has been recorded since 1945, 
an increase from 11.40 to 27.80. It is very unlikely 
that this represents a real increase in incidence. 
It is the result, rather, of a heightened awareness of 
the possibility' of thrombo- embolic complications and 
of more careful clinical scrutiny. The authors of th 
reports published since 1945 have directed their 
attention specifically to such complications in their 
clinical studies as a contribution to the evaluation 
of the use of anticoagulants. The most recent figures 
therefore probably present a truer picture of the 
frecÿuency of thrombo- embolic manifestations following 
crdiac infarction. It is easy to see how some of 
these conditions may have been missed in the earlier 
series since it is only comparatively recently that 
1 
attention has been drawn to the clinical picture of 
¡deep quiet venous thrombosis in the legs (Ho:m ans,l94 
;Minor/ 
11. 
Minor non -fatal pulmonary infarctions from such 
source may easily be diagnosed as pleurisy or other 
pulmonary infection or may fail of recognition altogetil- 
:er. Hines & Hunt (1941) reported a striking 
infrüuency of clinical diagnosis of pulmonary infarc- 
:tion. Out of 81 cases proved by post -mortem 
examination only 2 had been recognised in life. 
Clinicians tod ayare more keenly aware of the risk of 
pulmonary embolism following coronary thrombosis and 
are more suspicious of such features as slight chest 
pain and a rise in pulse, temperature and respiratory 
rate. 
The development of a second myocardial infarction 
during convalescence from an initial episode is well 
recognised clinically but has received little attention 
in the literature. Two observations have been record - 
:ed which are in close agreement. Nay & Barnes (1945) 
in their careful study of the incidence of embolic 
and thrombotic processes following acute myocardial 
infarction noted a secondary coronary thrombosis in 
14 of 100 cases. Wright et al. (1948) in a preliminary 
report on a combined investigation into the value of 
anticoagulants carried out in 16 rimerican hospitals, 
record in the control untreated series of 368 cases, 
extension of the original thrombosis in 90 and infarc- 
:tion of new areas of the myocardium in 6.50. 
It is clear from the foregoing considerations 
that/ 
12. 
that intravascular embolism and thrombosis are common 
events during convalescence from an episode of myo- 
cardial infarction. Tables II, III & IV. illustrate 
their frequency but not the severity and significance 
of such complications. Few of the reports listed 
state with what frequency they were the main cause of 
death or how serious their effects were in those who 
survived. Nay and Barnes (1945) considered these 
points and found that in their clinical series of 100, 
thrombotic or embolic processes were directly respons- 
:ible for 4 of their 13 deaths and were important 
contributory factors in 8 others. Out of 25 who 
survived thrombo- embolic complications, there were 
grave consequences in 17. Of these, 14 with a second 
episode of coronary thrombosis had a further impair - 
:ment of cardiac reserve and 3 became permanent inval 
:ids from cerebral damage. Hellerstein and Martin 
(1948) record that in 43 of their 160 post -mortem 
cases it is certain that thrombo- embolic lesions were 
important as a cause of death. Eppinger and Kennedy 
(1938) found such lesions to be a main or contributory 
cause of death in 49 of 200 cases. 
The time of onset of thrombo -embolic complications 
has been studied by Nay & Barnes (1945) and Wright et 
al.(1948). The former found that the great majority 
of secondary coronary thromboses and of cerebral 
vascular lesions occurred between the 4th and 20th day 
of illness, of pulmonary emboli between the 17th and 
36th/ 
13. 
36th day and of peripheral phlebothromboses between 
the 10th and 16th day. Wright reports that the 
incidence of thrombo- embolic complications is highest 
in the second week but is marked throughout the first 
four weeks. 
n description has been given of the types of 
thrombotic and embolic process which are prone to 
complicate acute myocardial infarction. Evidence has 
been proposed in a summary of the literature for the 
frequency, severity, significance and usual time of 
development of such complications. 
(b) Cause. 
The existence of a tendency towards intravascular 
clotting during the four weeks following an acute 
myocardial infarction is established but the ultimate 
causes of this tendency are not clearly understood. 
Wright (1946) suggests there is a profound change in 
the thrombosing balance of the blood which is either 
initiated by the local coronary thrombosis or else is 
the primary condition responsible both for the initial¡ 
thrombosis and for thrombosis in numerous other focal 
points at the same time. 
There is some evidence in the literature for 
Wright's suggestion. De Takats ( 1943) has shown 
that patients with coronary thrombosis have an increas- 
:ed resistance to heparin i.e. there is a disturbance' 
in the coagulation system with a tendency towards 
clotting/ 
14. 
clotting. Brambel (1945) found a shortening of the 
prothrombin_ time of diluted_ (12.5cA) plasma in coronary 
thrombosis but he does not state in what proportion 
of cases. Peters et äl.(1946) record a shortened 
prothrombin time of whole and /or diluted plasma in 
three -quarters of their cases of coronary thrombosis. 
They think that the clotting tendency is attendant 
upon vascular occlusion rather than the cause of it, 
since in some cases it did not make its appearance 
until the 2nd or 3rd day of illness. 
In striking contrast to these observations are 
the findings of Doles (1943) . He carried out routine 
prothrombin time estimations in 457 consecutive 
admissions to his care. 13 of these were suffering 
from or developed coronary thrombosis. He found in 
all a marked lowering of prothrombin level (i.e. an 
increase in prothrombin time) to 45 -60%, of normal. 
This was most marked 12 -48 hours after infarction. 
Doles was so impressed by these findings that he 
treated his cases with vitamin K with return of pro- 
:thrombin time towards normal and, he thought, clinical 
improvement. It is unfortunate that Doles has used 
a most confusing term in his report which he does not 
precisely define. He speaks of his cases showing a 
lowered prothrombin time per cent of normal. It is 
clear from the fact that he adopted treatment with 
vitamin K and from consideration of a previous publica+ 
:tion (Doles,1941) that by this term he means an 
actual/ 
15. 
actual increase in prothrombin time since in the 
latter report he indicated that 25 seconds is 1000 
prothrombin time and 30 seconds 800 prothrombin time. 
This unfortunate chaice of expression has been perhaps 
understandably misinterpreted in a widely read text- 
book. White (1947) quite erroneously quotes Doles 
as having reported a tendency to thrombosis with 
shortened prothrombin time in acute coronary occlusion. 
In a personal series of 19 cases of acute myo- 
:cardial infarction which are considered in detail 
in part V. of this paper, 8 showed a definite lower - 
:ing of whole or diluted (250) plasma prothrombin time, 
whereas 11 showed normal or raised figures. Evidence 
of a clotting tendency in the shape of an increased 
resistance to heparin was found in 7 out of 8 cases 
in which a heparin tolerance test was performed. 
In 3 of these 7 cases the prothrombin time was normal.' 
On the other hand, all cases showing a lowered pro - 
:thrombin time in whom heparin tolerance was estimated 
showédan increased resistance. These figures are 
too small to be of much significance, but they suggest 
that a clotting tendency can be demonstrated in some 
cases of myocardial infarction but not in all and 
that this tendency is better revealed by a heparin 
tolerance test than by reliance on estimations of 
prothrombin time. The methods of performance and 
significance of these tests is dealt with in detail 
in a later section. 
Apart/ 
16. 
.part from the probability of fundamental changes 
in the coagulation system of the blood there are 
certain factors which are known to be of importance 
in the genesis of intravascular thrombosis following 
myocardial infarction. There is increased viscosity 
of the blood in the presence of the haemoconcentration 
of "shock" or congestive heart failure (Best & Taylor) 
The lowered blood pressure is associated with a 
diminished cardiac output and a slowing of the circula- 
:tion. The consequent tendency to peripheral venous 
stagnation is enhanced by prolonged bed -rest with 
its attendant immobility of the legs and diminished 
respiratory excursion. Certain drugs commonly used 
in the treatment of cases of myocardial infarction 
have been held to increase the clotting tendency, 
though there is some conflict of evidence on this 
point. Drugs which have been incriminated are 
'digitalis, the methylated lanthines and the mercurial 
diuretics. 
de Takats et äl.(1944) have recorded that in 
both man and experimental animal digitalisation 
increases resistance to heparin. Macht, (1943) found 
that the various digitaloids added to shed blood in 
vitro hasten coagulation. Massie and his co- workers 
(1944) found that the coagulability of the blood was 
increased in each of 24 patients during administration) 
of full doses of digitalis. Massie's paper is open 
to criticism on the grounds that he compares a single 
figure/ 
17. 
figure, the lowest clotting time reached during 
digitalisation, with the average of clotting times 
recorded during a short period before digitalis. In 
the 2 control untreated cases which he charts there is 
a spontaneous fall in clotting time comparable to 
that in the treated cases. Furthermore, some of 
his treated. cu.ses show a return of clotting times to 
previous levels while still under digitalis. 
Sokoloff & Ferrer (1945) and Moses (1945) in 2 
short series of cases, 10 and 8 respectively, which 
are more convincingly presented than that of Massie, 
failed to find any support for the hypothesis that 
oral digitalisation_ increases the coagulability of 
the blood. 
On the other hand, skey & Teurath (1945) stress 
the danger of digitalis in coronary thrombosis. In 
32 cases of coronary thrombosis with auricular fibril - 
:lation and congestive heart failure 31 died, 13 of 
them with arterial emboli, whereas in 16 similar cases 
treated with quinicline, with a combination of 
quinicline and digitalis or receiving no medication 
there were no arterial emboli, though 11 died. 
Their best results were on combined quinicline and 
digitalis therapy. (It is of interest that quinine 
is reported to lower the prothrombin level in the 
blood (Dirk & Engelberg, 1945). It appears likely 
that quinicline has a similar action and hence may 
act as an antidote to digitalis in respect of its 
presumed/ 
18. 
presumed action on the coagulability of the blood.) 
They conclude that treatment by digitalis alone is 
contra -indicated in myocardial infarction with 
auricular fibrillation. Peters et al. (1946) record 
that of 17 cases of myocardial infarction with con - 
:gestive heart failure treated with digitalis, 9 died, 
most of them from embolism, but in 8 similar cases 
treated with digitalis and anticoagulants, there were 
no emboli and 1 death only - and that from renal 
complications. 
With regard to the methylated x anthines there 
appears to be general agreement that they induce a 
clotting tendency. Morawitz (1926) lists euphyllin 
as a substance which hastens coagulation. Field 
Larsen, quoted by Link (1943), have shown that 
large single doses of caffeine,theophylline and theo- 
:bromine given orally to dog, rabbit or rat induce 
hyperprothrombinaemia. Investigations by Scherf 
and Schlachman (1946) have revealed that there is a 
definite shortening of the prothrombin time and of 
the plasma coagulation time in man following an 
intravenous injection of aminophylline. 
The mercurial diuretics have been shown by 
Macht (1946) to produce a prompt and marked fall in 
clotting time when injected intravenously into 
experimental animals. Link (1943 -4) states that 




The various factors which may be considered to 
play a part in the genesis of the thrombo- embolic 
complications of acute myocardial infarction have 
been considered in detail. The evidence for a funda- 
:mental upset of the coagulation system of the blood, 
responsible both for the initial coronary thrombosis 
and for any subsequent thrombo- embolic process is 
strong but it is not complete. However, we must 
remember, with Goethe 'Blut ist ein ganz besonderer 
Saft' and the methods at our disposal of detecting 
changes in the thrombosing balance are at the best 
crude and incomplete. Estimation of the prothrombin 
time is not necessarily an accurate reflection of the 
prothrombin level (Macfarlane 1948) and even if it 
were completely reliable, it measures only one of 
many factors concerned in coagulation. The clotting 
time of whole blood in vitro is a crude device, sub- 
: j ec t to great variation and what happens in a test - 
tube or capillary tube may bear little relation to 
events within a living blood vessel. It appears 
likely that some form of heparin tolerance test is 
at present the best means at our disposal of assess - 
:ing the existence of a clotting tendency, though 
even this test gives negative results in a small pro 
:portion of cases with known intravascular thrombosis. 
(Hagedorn & Barker 1948). 
Disease of the arterial wall has always been 
considered the chief factor in the production of a 
coronary / 
20. 
coronary thrombosis. The local thrombus has 
usually been regarded as the mechanical result of 
necrosis or erosion of the atheromatous intima or 
of rupture of an atheromatous "abscess ". The exist - 
:ence of a clotting tendency has received little 
attention but it appears likely that it plays the 
primary role in those cases of coronary thrombosis in 
which little atheroma is demonstrable at post -mortem, 
and also in those cases in which coronary thrombosis 
is but one of many widespread thrombotic processes 
occurring simultaneously. Gibson (1949) has advanced 
the remarkable theory that a clotting tendency may be 
the cause not only of the local thrombosis but also 
of the disease of the arterial intima. He instances 
the findings of Duguid (1948) and Harrison (1948) . 
The former claims that the lesions commonly described 
as atherosclerosis may arise by organisation of a 
mural thrombus and substantiates his statement with 
convincing photomicrographs. Harrison went one step 
further and produced lesions indistinguisable from 
arteriosclerosis in the pulmonary arteries of rabbits 
by injecting finely; fragmented fibrin clot into their 
ear veins. Gibson concludes that increased coagul- 
:ability of the blood is the beginning and end of the 
process that ends in coronary thrombosis, and that it 
is for the biochemists to discover the origin of this 
disorder. The pathologists' findins require further 
confirmation and Gibson' s conclusions are premature 
though/ 
21. 
though thought- provoking. The warning sounded by 
Clifford Ullbutt in this very connection must be 
borne in mind. In discussing the causes of arterio- 
sclerosis he remarks "Our path is cumbered with 
guesses, presumptions and conjectures, the untimely 
and sterile fruitage of minds which cannot bear to 
wait for the facts, and are ready to forget that the 
use of hypotheses lies not in the display of ingenuity 
tut in the labour of verification." .t risk of 
standing retrospectively under i.11butt's obloquy it 
is suggested that cholesterol metabolism may have some 
bearing on Uibson's theory. There is a wealth of 
experimental evidence that disturbance of lipoid 
metabolism plays a part in the pathogenesis of athero- 
:sclerosis (Leary 1941, Dauber and Katz 1943). 
Though the level of blood cholesterol is variable in 
cases of myocardial infarction, conditions in which 
blood cholesterol is high, diabetes mellitus and 
myxoedema, are liable to be complicated by coronary 
disease. Morrison and his associates (1948) found 
hypercholesterol . emia in 60 of 75 patients under the 
age of 60 with proven acute coronary occlusion, 
though normal levels were found in 525& of 125 patienté 
over 60 with similar lesions. Hobson and Witts (1941) 
state that lipaemia lowers the prothrombin time. They 
found that the addition of lecithin to the reagents 
markedly lowers the prothrombin time of normal plasma,' 
that is it increases the prothrombin activity. It 
is/ 
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is suggested that the estimation of prothrombin time 
and heparin tolerance in patients with hypercholesterol- 
:aemia might yield information of value. Prothrombin 
time estimations carried out in 5 such cases (3 
coronary thrombosis, 1 diabetes mellitus and 1, 
surprisingly, extrahepatic obstructive jaundice of 
six weeks standing) were markedly lowered in all. 
It seems possible that there is an association between 
disorder of lipoid metabolism and changes in the 
thrombosing balance of the blood. 
(c). Conclusions. 
It has been shown that thrombo- embolic processes 
are frequently associated with episodes of acute 
myocardial infarction and that they increase the risk 
of death or subsequent invalidism. The causes of such 
complications have been considered and evidence pre- 
sented for the existence of a clotting tendency in 
the blood. The theory that such a disturbance of the 
coagulation system is the fons et origo of coronary 
thrombosis has been discussed and a tentative link 
forged with a fundamental disorder of lipoid metabol- 
:ism. 
Whether the existence of an alteration in the 
thrombosing balance of the blood is agreed to or not, 
the reality and significance of thrombo -embolic com- 
:plications of coronary thrombosis cannot be gainsaid.. 
If intravascular clotting can be prevented following 
such/ 
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such lesions, then it is likely that mortality and 
morbidity will be reduced. 
The trial of anticoagulants in acute myocardial 
infarction is based on sound pathological grounds. 
24. 
III . Anticoagulants. 
In animal experiments many substances have been 
been shown to have the property of inhibiting coagula- 
:tion. Most of these, such as hirudin, Germanin, 
neodymium, salvarsan, Liquoid Roche and_ various azo- 
dyes have proved inapplicable to human medicine on 
account of toxicity or some other insuperable dis- 
:advantage. Two anticoagulants, however, heparin 
and dicumarol have been applied with success to the 
prophylaxis and treatment of thrombo- embolic conditions 
in man. 
(a) Heparin. 
(i) Historical Review. 
Heparin was discovered by Howell and McLean in 
1916. They isolated it from tissue extracts of liver, 
muscle, heart, lymph nodes and later from lung. In 
a Harvey Lecture in 1917 Howell spoke of its lack of 
toxicity and of its possible future application in 
'the therapeutic treatment of disorders of coagulation' 
His prophecy was slow of realisation. But after 
Charles & Scott (1933) had developed an improved 
method of extraction and Jorpes (1935) had elucidated; 
its chemistry as a complex of esters of mucoitin 
polysulphtric acid, production was begun on a large 
scale. Murray and his associates (1936 & 1937) 
reported success in the prevention of experimental 
thrombosis in animals and Solandt and Best (1938) 
showed that prior heparinisation prevented the 
experimental/ 
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experimental cardiac infarction in dogs which is 
normally produced by intra- arterial injection of 
sodium ricinoleate. By this time it had already 
been established that heparin could be administered 
by repeated intravenous injection successfully and 
with safety to man (Howell & MacDonald, 1930) 
.(Hedenius & Wilander, 1936). Therapeutic trial was 
instituted by Crafoord in Stockholm and by Murray and 
his associates in Toronto and a series of papers from 
both centres during the next few years clearly indica -- 
:ed that thrombosis, post -operative or puerperal 
could be prevented by regular treatment with heparin 
in sufficient doses over an adequate period (Crafoord 
(1937, 1941, 1942) Murray et al. (1936, 1937)). 
The prophylactic effectiveness of heparin was 
expected but it was not generally foreseen that it 
would -rove even more useful as a therapeutic agent irk 
thrombosis. Crafoord (1939) and Murray and Best 
(1938) were the first to testify to this and since 
then a host of authors, too numerous to quote, have 
confirmed their findings. Crafoord and Murray first 
proved the curative value of heparin in peripheral 
phlebothrombosis and pulmonary embolism but subsequen 
reports have shown that it is also effective in other 
thrombotic conditions such as thrombosis of the centr 1 
retinal vein (Holmin 1938) thrombosis of the posterio 
inferior cerebellar artery (Magnusson 1938), 
mesenteric thrombosis (Murray and Mackenzie 1939, 
Luke 1943) and cavernous sinus thrombosis (Lyons 1941, 
Wiesenfeld/ 
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Wiesenfeld & Phillips 1944). The thrombolytic action 
of heparin has been demonstrated by Rabinowitch and 
Pines (1943). They showed that a course of heparin 
started on the first or second day after the induction 
of a jugular venous thrombosis in rabbits, caused the 
thrombus to disappear. 
The history of the discovery of heparin and of 
its sudden rise to therapeutic prominence many years 
later is a dramatic one com arable to that of penicillin. 
The expense and difficulty of its production had for 
too long been barriers to the experimental and clinica} 
assessment of its value and expense still to some 
,extent limits its more widespread exploitation in the 
prophylaxis of thrombo- embolisation. 
(ii) Pharmacology. 
lowell aptly described heparin as a physiologic 
:al anticoagulant. Researches by subsequent workers 
(Mellanby 1934, Quick 1935, Ferguson 1937 -8, tsrinkhous 
et al. 1939) have confirmed the physiological role of 
heparin in the coagulation system. It has a multiple 
effect, neutralising thrombokinase, acting as an 
antiprothrombin (an action which is inhibited by exces 
of thrombokinase) and also, in the presence of plasma 
and neutral salts acting as an antithrombin. Its 
mode of interference appears to be a physio -chemical 
reaction dependent upon the very strong electrical 
charge which its molecule carries, the strongest charg 
apparently of all organic compounds of the animal body 
(Jorpes/ 
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( Jorpes 1946). 
Fig. I. repres.;nts diagrammatically the Schmidt -Fuld 
Morawitz theory of coagulation and the action of 
heparin in the coagulation system. 
Scheme of coagulation of the blood. 
Fibrinogen Calcium Prothrombin Thrombokinase 





---- m Neutralises. 
Careful investigations by Jorpes (1936) 
Holmgren & Wilander (1937) have show that the site 
of formation of heparin is in the mast cells which 
are found widespread in the body tissues, mainly in 
the connective tissue in the vicinity of capillaries 
and in the walls of blood vessels. As would be 
expected from the fact that heparin is a normal 
constituent of the body, its toxicity is low. True 
anaphylactic reactions have occasionally been recorded 
in a very small proportion of cases ( Jorpes 1946) 
Cortes and his associates (1947) were unable to pro- 
duce, in Schultz -Dale studies, any evidence of 
anaphylactic sensitivity in the guinea -pig following 
attempts at sensitisation with heparin. The danger 
of haemorrhage appears to be surprisingly small. 
Haematomata may appear post- operativele but this risk 
is/ 
28. 
is obviated if heparinisation is not started until 
24 hours after operation. Transient insignificant 
haematuria has been recorded (Ershler & Blaisdell 1941, 
Priestley, Essex & Barker, 1941). Haemorrhage into 
the pleura following heparin treatment for pulmonary 
embolism has been infrequently reported. In respect 
of the 2 cases mentioned by Falconer (194.3) Jorpes 
states that in one, which died of pulmonary embolism, 
the dose of heparin was totally inadequate and in the 
second it was excessive. In the rare event of severe 
haemorrhage due to heparin the intravenous injection 
of 5 to 10 cc. of 1,6 protamine sulphate will restore 
the clotting time of the blood instantaneously to 
normal. Heparin is usually administered intravenous- 
:ly either by intermittent injections or by a continu- 
:ous drip. The latter method is theoretically sounder 
since the blood clotting time returns to normal within 
3 hours of a single injection but the former is the 
more common and the more generally useful method, 
and has proved quite as effective in practice. The 
dosage varies from 5,000 - 12,500 units every 4 -8 hrs., 
the exact dose being controlled by daily estimations 
of the clotting time. Some simple methods of over- 
:coming the difficulties of arranging for repeated 
intravenous injections are considered in part V. of 
this paper. Intra- muscular injections of heparin 
have been recommended by Walker (1945) but in the 
authors experience, the effect on the clotting time is 
capricious/ 
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capricious and unpredictable and haematomata may form 
at the site of injection. 
kttempts have been made to obviate the tedium 
of repeated intravenous injections and to economise 
in heparin by means of preparations designed to delay 
the absorption of heparin from a subcutaneous depot 
(Loewe & Rosenblatt, 1944) or an intramuscular one 
(Vorzimer et al. 1948, Stats & Neuhof 1947). The 
value of such preparations has not been widely confirm - 
:ed and their use has not been considered in the 
present study since they are not suitable for combined 
heparin- dicumarol therapy. 
The historical development of heparin as a 
therapeutic agent and its present place in prevention 
and treatment of thrombotic conditions have been 
reviewed. Its physiological aspects, mode of action, 
method of administration and disadvantages have been 
briefly considered. It is concluded that there are 
sound pharmacological grounds for the trial of heparin 
in acute myocardial infarction but that its expense and 
the necessity for parenteral administration make it 
impractical to use heparin throughout the period of 
risk of thrombo -embolic complications. 
(b) Dicumarol 
(i) Historical review. 
The story of the emergence of dicumarol as a 
potent anticoagulant is an absorbing one. ns is 
common in biology, the discovery of its therapeutic 
value/ 
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value was incidental to an apparently unrelated piece 
of research. "Sweet- clover disease" of cattle, which 
is characterised by massive, usually fatal, haemorrhages 
had interested and baffled veterinarians for many 
years. Careful and determined research at the 
Wisconsin Agricultural Research Station finally led 
to the isolation from 'spoiled sweet- clover' of the 
causative agent in crystalline form (Campbell 83 Link 
1941). It was identified chemically in the same 
year by Stahmann, Heubner ¿ Link as 3.3'. methylene - 
bis (4 hydroxycoumarin) and finally synthesised by 
the same team, who showed that it caused haemorrhage 
by lowering the prothrombin activity of the blood. 
These studies, which are admirably presented by Link 
in the Harvey Lectures (1943 -4), were carried out at 
a time when the increasing use of heparin in the 
treatment of thrombo- embolisation had made anti - 
:coagulant therapy the subject of frequent discussion 
and the possibilities of the new substance were 
immediately realised. It was named "dicumarol" by 
the Council of Pharmacy of the American Medical 
Association and animal experiment and clinical trial 
were immediately instituted. 
Administration of dicumar of was shown to 
prevent the arterial and venous thrombosis which can 
be produced in dogs by a variety of experimental 
techniques (Bollman & Preston 1942, Dale do Ja,acres 
1942, Richards Cortell 1942). Extensive clinical 
trial/ 
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trial has affirmed the value of dicumarol as a 
prophylactic and therapeutic agent in thrombosis. 
steady stream of favourable reports has appeared since 
1942. In prophylactic studies the largest and most 
convincing series have been the 1448 cases of Bruzelius 
(1945) the 1000 surgical cases of Barker and. his 
associates (1945) and Allen's (1947) series of 1686 
cases. All these observers found a marked reduction , 
in thrombo- embolic complications in cases receiving 
dicumarol prophylactically. The same workers also 
found, in smaller series, that dicumarol is effective 
in the treatment of established thrombosis. Zilliadus 
(1946), in a study of surgical, obstetric and medical 
cases, found that in 214 patients with deep venous 
thrombosis who received no specific treatment, the 
average length of confinement to bed was 35 days, 
pyrexia persisted for 21 days on the average and 59 
patients developed pulmonary embolism. On the other 
hand in 131 similar cases treated with dicumarol, the 
average confinement to bed was 9.5 days, the average 
duration of pyrexia was 8.2 days and pulmonary 
embolism occurred. in only 2. 
The reports do not indicate that dicumarol is 
100g6 effective in preventing venous thrombosis or the 
extension of an already existing thrombus but that the 





Link and his co- workers showed that dicumarol 
acts by depressing the prothrombin activity of the 
blood. The effect is delayed for a variable period 
after the initial dose of dicumarol - usually from 
24 -72 hours. The exact mechanism of production of 
hypoprothrombinaemia is not clearly known but it is 
generally believed that the drug acts by preventing 
synthesis of prothrombin in the liver. There is also 
evidence that it diminishes the production of fibrin - 
:ogen in the liver (Jaques & Irish 1944). The effect 
of a given dose in different individuals is unfortun- 
:ately highly variable. Dosage from day to day can 
be controlled only by the daily estimation of pro - 
:thrombin time. This is a tedious procedure and is 
only an indirect and not altogether satisfactory means 
of assessing the level of prothrombin in the blood. 
However it is the only method at present available. 
It is obvious that treatment by dicumarol 
uncontrolled by prothrombin time estimations is very 
likely to produce in man an attack of the haemorrhagicl 
sweet -clover disease of cattle. It has also 
unfortunately become clear that careful control of 
dosage by daily prothrombin estimations will not 
entirely obviate the risk of haemorrhage in a small 
number of cases. In Bruzelius' whole series of 1656 
cases treated with dicumarol, haemorrhage occurred in 
13 with 3 deaths. Evans (1944) reported 8 cases of 
haemorrhage in a series of 55 with death in 2. In 
the/ 
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the more recent report of Allen (1947) minor 
haemorrhage is recorded in 3.1 of 1686 cases, major 
bleeding in 1.9g6 and there were 2 deaths from 
haemorrhage. Allen states that dicumarol was not 
the cause of bleeding in one of these cases and its 
responsibility was doubtful in the other case. Reich 
and Eisenmenger(1948) have recorded the occurrence 
of frank haemorrhages in cases with a "safe- levels` of 
prothrombin and have noticed that very high, apparently 
dangerous, prothrombin times are not necessarily 
;attended by bleeding. 
Prothrombin deficiency induced by dicumarol 
can usually be corrected by large doses intravenously 
of a Vitamin K analogue. Cromer ¿. Barker (1944) 
showed that intravenous injection of 64 mg. of 
menadione bisulphite was effective in 35 out of 37 
cases of dicumarol hypoprothrombinaemia and that 
haemorrhage was promptly controlled. The return of 
prothrombin levels to normal started 2 hours after the 
injection and was complete in 18 hrs. Reich & 
Eisenmenger (1948) found that 60 -120 mg. of water 
soluble vitamin K intravenously successfully restored 
normal prothrombin levels in all hyper- reactors to 
dicumarol. De Bakey (1943) on the other hand, state0 
that vitamin K has no effect on haemorrhage due to 
dicumarol but produces no evidenceln support of his 
statement. Miller and Druc quer (1948) found that 
vitamin K was ineffective in their case of dicumarol 
poisoning but they administered the vitamin intra- 
:muscularly/ 
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:muscularly and they do not state in whát dosage. 
It is unanimously agreed that transfusion of 500 cc. 
of fresh blood will temporarily raise the prothrombin 
level sufficiently to control haemorrhage, but in 
severe cases the level may fall again and further 
transfusion may be required. Allen (1947) suggests 
that careful prothrombin time estimations and the use 
where necessary, of intravenous vitamin K and blood 
transfusion will prevent any fatalities from dicumaro J. 
Intravenous administration of large doses of the sodiim 
salt of dicumarol to dogs has an immediate toxic effect 
with hyperglycaemia, pyrexia (without hypoprothrombin - 
:aemia) and circulatory collapse with capillary 
dilatation, Wakim & Gatch (1943). Such an effect has 
not been described in marl on therapeutic oral doses 
but evidence of damage to capillaries has been 
described in the shape of petechiae and positive 
capillary fragility test, usually in cases with 
dangerously low prothrombin levels but also in some 
cases with prothrombin times at a safe level within 
the therapeutic range (Reich & Eisenmenger 1948). 
Hepatic necrosis occurs in 500 of animals 
receiving massive doses of dicumarol but no liver 
damage has been recorded in man even in cases which 
have suffered profuse haemorrhage from accidental 
overdo sage. 
Dicumarol therapy is contra- indicated in 
haemorrhagic blood dscrasias, in conditions in which 
there/ 
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there is likely to be a low prothrombin level in the 
blood, such as obstructive jaundice, the sprue syndrome 
and advanced hepatic disease and also in renal failure 
which tends to prevent elimination of the drug. The 
administration of dicumarol is also held to be unwise 
in the presence of ulceration of the alimentary tract, 
owing to the risk of haemorrhage. The danger of 
haemorrhage under dicumarol treatment must be viewed 
in a proper perspective and must be balanced against 
the benefits of such therapy. b.11en (1947) in his 
study of 1686 surgical cases receiving dicumarol 
prophylactically or therapeutically calculated the 
expected incidence of thrombo- embolic complications 
'and the expected death rate from such complications 
on the basis of the careful statistical study of _barker 
and others (1940). He found that approximately 73 
lives were saved by the use of dicumarol and 211 
patients were spared venous thrombosis and pulmonary 
embolism. There was only 1 death from haemorrhage 
that might possibly have been attributed to dicumarol. 
The evolution of dicumarol as an anticoagulant 
and its value in the prophylaxis and treatment of 
venous thrombosis and pulmonary embolism have been 
briefly reviewed. A. short account has been given of 
its mode of action and disadvantages. It is felt 
that there is sound justification for the controlled 
and cautious trial of dicumarol in the management of 
cases of acute myocardial infarction. 
36. 
(c) Combined heparin - dicumarol therapy. 
Neither heparin nor dicumarol is the ideal 
anticoagulant. Heparin has the disadvantage of 
expense and the need for parenteral administration 
which counterbalance its safety, ease of control and 
rapidity of action. Dicumarol, though cheap and easy` 
to administer, requires the employment Of a tedious 
and time -consuming laboratory prodedure to control 
dosage and, even so, its use is by no means free of 
risk. It carries the further drawback that its 
effect is delayed for some time after administration 
and continues for a variable period after the drug 
is stopped. 
Some of these disadvantages can be overcome by 
combined heparin and dicumarol therapy. If administra- 
:tion of both anticoagulants is started simultaneously 
an immediate effect is obtained from the heparin and, 
when the dicumarol takes effect, usually in 2 -3 days, 
then the heparin can be discontinued. Further 
injections of heparin can be given, if at any time 
the prothrombin level rises above the intended thera- 
:peutic range. 
Such a technique, which is considered in detai 
in part V. of this paper, would appear to be the best 
method at present available for the application of 
anticoagulants to the treatment of myocardial infarc- 
:tion. Most workers in this field have used dicumarl 
alone on the grounds that thrombo- embolic corn licatio s 
are/ 
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are not commonly observed in the first 2 or 3 days 
following the episode of infarction. It is very 
likely, however, that spreading retrograde thrombosis 
and possibly mural thrombosis do occur in some cases 
during this period. Furthermore there is sufficient 
experimental and clinical evidence for the contention 
that anticoagulants actually dissolve a preformed 
clot. Loewe and his associates (1947 -1948) showed 
conclusively that both heparin and dicumarol can 
cause resumption of patency in veins of experimental 
animals which have been thrombosed for periods as 
long as 2 weeks. The recognised therapeutic efficacy 
of anticoagulants in established deep venous throm- 
bosis can hardly be explained on any other grounds 
than recanalisation by dissolution of thrombus. Such 
an action is strong support for the use of heparin at 
the earliest possible moment in cases of coronary 
thrombosis in the hope that patency might possibly 
be restored to the blocked vessel. 
38. 
IV. Anticoagulants in Myocardial Infarction. 
Review of literature. 
Solandt & Best demonstrated the effectiveness 
of heparin in preventing experimental myocardial 
infarction in dogs in 1938 and later showed (Solandt, 
Nassim & Best, 1939) that heparin was equally effec- 
:tive in preventing the experimental production of 
mural thrombi in dogs. Though they concluded from 
this experiment that clinical trial of heparin was 
indicated, clinicians were slow to follow up their 
suggestion. It was apparently felt that heparin 
would increase the risk of intimal haemorrhage which 
was at that time considered to be an important factor 
in the production of coronary thrombosis (Graybiel 
& White 1939). It has more recently been shown 
(English & Willius 1943) that intimal haemorrhage, 
though a common phenomenon in coronary atherosclerosis, 
plays a major role in the production of coronary 
thrombosis in very few instances. 
The first clinical trial of anticoagulants 
in coronary thrombosis appears to have been made by 
Holten & Lundsteen (1942) but their report unfortunate - 
:ly has not been accessible to the author. The first 
available clinical study is that of Wright (1945) who 
treated his first case with dicumarol in 1942. He 
selected patients to receive dicumarol who had 
suffered repeated episodes of thrombosis in different 
branches of the coronary tree or whose original 
thrombus had propagated or who had suffered repeated 
embolic/ 
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embolic incidents, pulmonary or systemic. These 
indications were based on analogy with the rationale 
of anticoagulant therapy in other forms of thrombo- 
embolic disease. The use of dicumarol was not long 
restricted to patients with such complications and a 
number of reports have appeared in the American 
literature on the use of anticoagulants in all cases 
of myocardial infarction without selection. An 
extensive combined investigation on these lines is at 
present being pursued in 16 American hospitals under 
the auspices of the American Heart Association. 
Before these reports are reviewed, some interes 
:ing observations that have recently been recorded in 
relevant experimental and clinical studies will be 
considered. Blumgart and others (1948) studied the 
effect of dicumarol on the heart in experimental acute 
coronary occlusion in dogs. They found no difference 
between treated and control animals in respect of the 
incidence and magnitude of haemorrhagic extravasations 
in the endo- and pericardium, the extent of microscopi 
miliary haemorrhages, the size and healing of infarcts 
the presence of thrombi in smaller arteries in the 
infarcted area and the development of an anastomotic 
circulation. They found that severe hypoprothrombin- 
:aemia in 3 dogs caused no increase in haemorrhage. 
They conclude that dicumarol produces no adverse 
effects on the myocardium of dogs which retard the 
healing process or development of collateral circulati 






Leroy & Nalefski (1948) in a similar study, reached 
the same conclusion. They found no evidence that 
intimai haemorrhage was of significance in any of 
their cases. Serial electrocardiograms did not show 
any consistent significant difference between treated 
and control animals. 
These reports suggest that the action of 
dicumarol, recorded by Loewe et al (1948), of 
dissolving a preformed clot and opening up collateral 
channels, does not operate in coronary thrombosis. 
However it must be remembered that in the experiments 
of Blumgart and Leroy a coronary artery was ligated 
and therefore patency could not be restored whereas 
in clinical coronary thrombosis the dissolution of 
the clot and opening u of the lumen of the vessel 
is theoretically possible. That such an event is 
unlikely is shown by the studies of Balkin & Gootnicl 
(1948) on the effect of dicumarol on the elec trot rdio- 
:gram. They found that the administration of 
dicumarol for several weeks had no effect on the 
electrocardiograms of patients with cardiac infarction, 
nor incidentally of normal subjects nor of patients 
with varying types of cardiovascular disease. seria 
electrocardiograms of those with infarction showed th 
expected progressive changes of healing infarction. 
The rate of progress did not differ materially from 
that observed in patients not receiving dicumarol. 
These studies appear to establish that d.icumar1 
has neither a harmful nor a beneficial effect on an 
area/ 
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area of infarcted cardiac muscle. If dicumarol 
therapy lessens mortality from myocardial infarction 
it must be by prevention of thrombo- embolic complica- 
:tions. These conclusions probably apply to heparin 
therapy also but not with certainty, for Loewe (1948) 
has shown that heparin is more effective than dicumard1 
in dissolving a preformed in vivo clot. 
These side -lights on anticoagulant therapy 
are of interest but assessment of the value of 
anticoagulants in the treatment of myocardial 
must of course ultimately depend on their observed 
effect in actual clinical practice. The experiences 
of the various workers in this field in respect of 
reduction of mortality rates, reduction in incidence 
of thrombo- embolic complications, methods of control 
and incidence and severity of toxic effects will be 
discussed and summarised. 
Wright (1946), in his second publication in 
this connection, recorded a mortality rate of 2596 in 
his initial series of 43 complicated cases as con - 
:trasted with an anticipated mortality of 60 -70%. In 
uncomplicated cases, in which he anticipated a 
mortality of 20 -30, the death rate was 12yß. In 38 
of the 43 complicated cases there was no further 
evidence of extension of the thrombosis or of addition - 
:al thrombi or emboli after the start of dicumarol 
therapy. Toxic effects were confined to minor 
purpuric eruptions in three patients. In 8 autopsies 
no/ 
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no evidence was found of damage attributable to 
dicumarol. Wright'did not study a control series 
and the figures that he quotes of anticipated 
mortality, were based, on his own admission, on 
clinical impressions and not on any adequate statistic 
:al data. It may be objected that he placed. the 
,anticipated risk too high. He quotes case histories 
of patients in whom a series of thrombo- embolic 
episodes ceased promptly under the effect of dicumarol. 
He concluded that dicumarol was likely to prove of 
value in cases of coronary thrombosis complicated by 
further thrombo -embolic processes but that his 
material did not justify the conclusion that dicumaroll 
would effect the results in uncomplicated coronary 
thrombosis. 
In series subsequently reported no such selection 
of cases has been exercised and anticoagulant therapy 
has been applied to cases of myocardial infarction 
whether complicated or not. Peters, Guyther & Brambel 
(1946) selected their cases for dicumarol therapy on 
different grounds. They noted that 3 out of 4 cases 
of coronary thrombosis showed a clotting tendency 
as judged by a definite lowering of the prothrombin 
time of 12.5 %, diluted plasma and regarded this as 
their indication for anticoagulant administration. 
In 50 treated cases there were 2 deaths, 1 from 
heart failure, 1 from renal failure as compared with 
13 deaths, 6 of which were from emboli, in 60 controls. 
They do not state if the 60 controls included these 
cases/ 
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cases which did not show a clotting tendency, nor if 
any of the latter developed thrombo- embolic complica- 
:tions. Their 50 treated cases showed only 1 embolic 
incident. Dicumarol therapy had been delayed in this 
case until the 8th day. On the 9th day there was 
twitching and weakness of the left hand and on the 10t 
when the prothrombin time showed that he was well 
under the influence of dicumarol, the patient had a 
generalised convulsion and developed a transient left 
hemiparesis. Recovery thereafter was uneventful 
and the authors thought that the delay in dicumarol 
therapy might well have favoured the building up of 
a sizeable mural thrombus. In the 60 untreated cases 
there were 10 with clinical embolism, pulmonary, 
cerebral or peripheral. The authors also studied the 
effect of digitalis. 17 of the 60 control cases 
received digitalis for congestive failure and 9 of 
these died, most of them from embolism, whereas of 8 
treated cases receiving digitalis, only 1 died (from 
renal complications). Few toxic reactions from 
dicumarol were noted in this series. Microscopic 
aematuria occurred in 3, there were no gross 
aemorrhages and no delayed toxic effects. It is 
noteworthy that the prothrombin level was maintained 
at 35 -50g6 of normal, a level which later authors regar 
as too high (Wright et al. 1948) and dicumarol was 
administered for 6 weeks, which is considerably longer 
than in any other series. The authors concluded that 
urther clinical evaluation of dicumarol in myocardial 
infarction/ 
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infarction was warranted. 
Nichol (1947) treated with dicumarol all cases 
of myocardial infarction seen by him from June 1943 to 
June 1946. In 68 attacks occurring in 62 patients 
there were 11 deaths - a mortality rate of 160. 3 of 
the deaths occurred before dicumarol could take effect 
There were 2 possible embolic incidents under dicumaro 
a doubtful pulmonary embolism, and a mesenteric arteri 
occlusion. in 8 post mortem cases there was no 
evidence of mural thrombi or emboli nor of haemorrhage 
or liver damage. 
Parker & Barker (1947) report the use of anti - 
:coagulants in 50 cases, 10 on combined heparin - 
dicumarol therapy, 40 on dicumarol alone. There were 
5 deaths, 2 from acute heart failure, 2 from congestiv 
failure and 1 from a second coronary thrombosis. 
Vascular complications occurred in 4, 2 patients 
developing a second coronary thrombosis and 2 cerebral 
emboli. There were also 2 cases of pulmonary 
embolism and 2 of peripheral arterial occlusion 
before anticoagulants were started. Haemorrhage 
occurred in 3 cases, haemarthrosis of the knee in 1, 
epistaxis in 1 and haematuria in 1. They are the 
first authors to point out the difficulty of control- 
:ling the prothrombin level. They endeavoured to 
keep it within the range of 10 -300 of normal, but 
found that it fell too low in 12 cases, 6 of whom 
required vitamin IC to restore it to the optimum range. 




the desired deficiency of prothrombin and in one of 
these a second myocardial infarction occurred. They 
concluded from their findings that the continued use 
of heparin and dicumarol in coronary thrombosis was 
warranted. 
The series reviewed above, with the possible 
exception of that of Peters and his associates, carry 
less weight than they might because of the lack of 
'comparable control series of untreated cases. Glueck 
and her co- workers (1948) obtained a control group by 
administering anticoagulants to every alternate case 
of myocardial infarction admitted to their hospital. 
Their groups were reasonably comparable in respect 
of age, sex, previous heart disease and cardiac 
enlargement. Treatment was by simultaneous dicumaral 
by mouth and heparin by continuous intravenous drip 
(300 mg. heparin in 1 litre of 5 ¡"0 glucose - 20 to 35 
drops per minute) until prothronbin level was 2O -30A, 
when heparin was stopped. In 25 treated cases there 
were 3 deaths and 1 doubtful embolic complication (a 
transient facial palsy and aphasia) whereas in the 
control untreated group of 25 there were 8 deaths and 
6 cases with emboli. The authors state that in 
many cases the intensity of the pain and its duration 
seemed markedly reduced by the intravenous administra- 
:tion of heparin in glucose but think that further 
observations are necessary before conclusions can be 
drawn. Jill the treated cases who died were found to 
have massive infarction at autopsy - none showed mural 
thrombi/ 
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thrombi or emboli. 2 patients showed evidence of 
haemorrhage probably attributable to c.icumarol, one 
with a prothrombin concentration of 130 had gross 
haematuria, the other had one tarry stool when the 
prothrombin fell to 170. The former responded well 
to intravenous vitamin K., the latter required no such 
treatment and had no recurrence of melaena. In a 
brief addendum to their report, the authors record 
their study of a further 19 cases in each series, 
treated and controls, and give final consolidated 
figures of 200 mortality and 70 emboli in those receiv- 
:ing anticoagulants and 450 mortality and 270 emboli 
in the control series. The authors do not claim any 
dramatic success for anticoagulant therapy but are 
content to observe that it does not seem to do any 
harm to cases of myocardial infarction: 
Greisman and Marcus (1948) administered dicumarol 
to 75 cases and studied 100 comparable cases not 
receiving anticoagulants. There were 7 deaths, 2 of 
which were due to cerebral thrombosis, in the treated 
cases and 35 deaths in the control series. Thrombo- 
embolic lesions occurred in 3 of the treated series 
and in 21 of the controls. They omitted from both 
,series, treated and controls, cases which died within 
48 hrs. of admission to hospital. This omission has 
the effect of increasing the relative superiority of 
the mortality rate in treated cases over that in the 
controls and makes their figures not strictly comparable 
with/ 
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with the mortality rate generally reported in other 
series which are not selected in this way. 17 
control cases required digitalis for congestive heart 
failure and of these, 9 died, 5 of them from emholi, 
whereas in 15 cases with congestive failure requiring 
digitalis among the treated group there were only 3 
deaths, none of them from embolic processes. The 
authors state that prothrombin estimation every second 
day is adequate for control of dicumarol dosage. 
They regard a prothrombin level of 10 -309 of normal 
as the optimum therapeutic range and found that where 
bleeding occurred in the presence of a prothrombin 
level lower than 100, intravenous vitamin K controlled 
the bleeding and raised the prothrombin above 10 
within 24 hours. No major haemorrhagic episodes 
were seen under the effect of dicumarol but 2 patients 
had minor rectal bleeding from haemorrhoids and one 
had macroscopic haematuria. The authors feel that 
dicumarol should be administered to patients with 
acute myocardial infarction, particularly those who 
are in congestive heart failure and are receiving 
digitalis. 
Among 3u0 varied cases treated with anticoagul- 
ants, prophylactically or therapeutically, Reich and 
Eisenmenger (1948) studied dicumarol therapy in 24 
cases of myocardial infarction. There were 4 death: 
in this small series, 2 from pro;ress.ive cardiac 
failure, 1 with clinical and electrocardiographical 
evidence/ 
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evidence of progressive cardiac damage and 1 from a 
fresh episode of coronary thrombosis whilst receiving 
dicumarol. A similar but non -fatal episode occurred 
in one other case under adequate dicumarol dosage. 
They record no other thrombo- embolic complications and 
advance the opinion that anticoagulants are unable to 
influence the development of further coronary thrombos- 
:es where degenerative disease is sufficiently advanc 
:ed but that thair main usefulness lies in preventing 
embolisation from peripheral veins or mural thrombi. 
The prothrombin level which they recommend is the 
upper level of the therapeutic range recommended by 
other workers. They state that the object is to 
prolong the prothrombin time by Quick's method to 
twice normal. This is equivalent to a prothrombin 
level of 300 and may not be quite low enough. However 
they quote cases to show that haemorrhage may occur 
at reputedly safe prothrombin levels and also that 
extremely low pronombin levels may occur :ithout 
bleeding. They stress the great individual variation 
in response to dicumarol. They found that some 
coronary patients, particularly those with congestive 
heart failure and presumable reduction in renal blood 
flow, were unduly sensitive to dicumarol. McCall 
(1948) treated with dicumarol 71 cases of myocardial 
infarction, consecutively admitted to his care. He 
omitted from his series 3 patients who died within 
48 hrs. of admission. There were 9 deaths, 1 from a 
pulmonary/ 
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pulmonary embolism on the 6th day, 1 from progressive 
extension of a second infarction on the 20th day, 6 
from heart failure and 1 from a ruptured ventricle. 
Thrombo- embolic complications numbered 2 only. In 
post -mortem cases no mural thrombi were found. Gross 
haematuria occurred in 3 cases, but was readily con - 
:trolled by intravenous injection of 60 mg. of 
menadione bisulphite. 2 cases had mild epistaxis. 
The authors record an unexplained difficulty in main - 
:taining the desired prothrombin level in 21 cases. 
In 10 of these a lapse of 4 days occurred initially 
before a therapeutic range was attained. On 4 
occasions the prothrombin fell to dangerously low 
levels without haemorrhage. There were 6 patients in 
whom effective therapeutic control lapsed for a day or 
more without mishap. The authors conclude that thougel 
certain features of dicumarol therapy are undesirable, 
the therapeutic approach is sound. 
The most significant and authoritative analysis 
of anticoagulant therapy of myocardial infarction that 
has yet appeared is embodied in the preliminary report 
from the pen of Wright and his associates (1948), on 
the combined investigation at present being pursued in 
16 American Hospitals. The plan in this project has 
been to administer anticoagulants, either dicumarol 
alone or combined heparin and dicumarol at the dis- 
:cretion of the physician in charge of the case, to al 
patients with myocardial infarction admitted on odd 
days/ 
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days of the month and to withhold such treatment from 
those admitted on even days the latter group L o serve 
as control cases. The anticoagulant, odd -day group 
has numbered 432 cases and the control, even -day, 368. 
The groups were comparable in age, sex, history of 
previous infarction and severity. l2ío of the control 
group did receive some anticoagulant therapy, usually 
for short periods only, due to pressure of the family 
or private physician. In the treated group, 8líß 
received dicumarol only, l4 %7 dicumarol and some heparin, 
3 %7 no anticoaMulants because of specific contra - 
indications and 2 no anticoagulants because of 
miscellaneous errors. 
In presenting their figures the authors have 
made small conservative corrections for some of these 
anomalies. In the control group, rates have been 
corrected for exceptions to the no anticoaguant' 
rule; the figures differ only slightly from those 
actually reported but are believed to present a truer 
picture. In_ the treated group rates have been 
justifiably corrected for erroneous omission of anti- 
:coagulants but not for those cases in which anti - 
:coagulants have been withheld because .of specific 
contra -indications. Such omissions are held to be 
disadvantages inherent in this type of therapy. 
The death rates were l5;6 in the treated group, 
24 in the controls. The greatest improvement was in 
those who had suffered one or more thrombo- embolic 
complications/ 
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complications, for whom the figures were controls 10,h 
deaths, treated 3,. Mortality was greatest in the 
first 2 weeks but was significantly high in 3rd and 
4th week also. Study of death rates by age groups 
showed great reduction of mortality in treated patients 
over 60. In those under 60 there was no significant 
difference between the treated and control groups. 
The incidence of thrombo- embolic complications recognis- 
: ed clinically was 36%, in the controls and 14¡0 in those 
treated - but of these, occurred in patients not 
receiving anticoagulants and 2.5 occurred during the 
first 3 days of dicumarol treatment giving a corrected 
incidence of 6.5o thrombo- emboli in those actually 
under the influence of anticoagulants. Study by age - 
groups showed that anticoagulants were apparently 
equally effective at all ages in preventing thrombo- 
embolic complications. Study of the incidence of 
different types of thrombo-embolic process showed that 
each type occurred much less frequently in treated 
cases. This applied equally to spreading coronary 
thrombosis, second episode of coronary thrombosis, 
pulmonary, cerebral and peripheral embolism and 
peripheral venous thrombosis. 
The authors found that haemorrhagic manifesta - 
:tions occurred in 6 of the control group and in 12A 
of those treated, but of the latter 2 were not 
receiving anticoagulants and in haemorrhage was 
definitely not due to the therapeutic agent. Out of a 
total/ 
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total of 30 haemorrhagic incidents due to dicumarol, 
only 1 was severe. There were no deaths due to anti - 
:coagulants. 
In this series dicumarol has been administered 
for 30 days as a minimum, preferably for 30 days after 
the last thrombo- embolic episode. The elected thera- 
:peutic prothrombin level has been a prothrombin time 
by Link- Shapiro technique of 30 -35 secs., equivalent 
to a prothrombin of 20 -30;x. The authors think that 
where thrombotic processes have occurred in patients 
receiving dicumarol it has been because the prothrombin 
had not fallen to the therapeutic level. Out of 38 
complications under dicumarol 4 only occurred in 
patients whose prothrombin time had been adequately 
prolonged. for 3 days preceding the complication. 
Wright and his associates state that the 
results in every category studied indicate that the 
use of anticoagulants improves strikingly the outlook 
of the patient suffering from myocardial infarction. 
They point out that, though in their series the 
mortality under 60 was not improved, this is because 
the younger patient is more likely to survive a 
thrombo- embolic complication, but that he does so at 
the risk of a permanent disability, a risk which is 
greatly diminished by anticoagulant treatment. They 
conclude that anticoagulant therapy should be used in 
all cases of coronary thrombosis with myocardial 
infarction unless a definite contra -indication_ exists 
and/ 
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and that the hazards from haemorrhage due to anti- 
:coagulants are not sufficient to contra-indicate 
their use provided adequate laboratory- control is 
available. 
While all the authors reported above record, 
with greater or less vehemence, their favourable 
impressions of the anticoagulant therapy of myocardial 
infarction, a more clear -cut picture may be drawn by an 
analysis and summary of their results and by a brief 
consideration of some points on which there is a 
difference of opinion. 
The recorded mortality rates under anticoagulant 
therapy are summarised in Table V. and compared with 
the rates of control series where such were studied. 
Table V. Deaths in cases of myocardial infarction 
treated by anticoagulants and in control cases not so 
treated. 
authors. i-Lnticoag.Cases. Control Cases. 
No .treat- Deaths No. Deaths. 
:ed. 
Wright (1946) 76 15 
Nichol (1947) 68 11 
X.-Peters et al. (1946) 50 2 60 13 
Parker & Barker (1947) 50 5 - - 
`reisman & Marcus (1948) 75 7 100 35 
Glueck (1948) 44 9 44 20 
Reich & Eisenmenger (1948) 24 4 - 
- -McCall (1948) 71 9 - - 
Wright et äl.(1948) 432 65 368 88 
Totals 890 127 572 156 
Death rate 14.3; m 27.3¡ 
( Cases dying within 48 hrs. of admission not iraluöed) 
Tt/ 
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It is seen that the mortality rate is almost 
halved in cases receiving anticoagulants. The 
,figures shown are statistically significant. The death 
;rate in the control series correlates with the figures 
of 25 -300 given by Bedford (1936) as the expected death 
rate in the 6 weeks following an episode of coronary 
!thrombosis. In 3 of the series noted in table V. 
cases dying within 48 hrs. of admission to hospital 
were not included. This omission invalidates com- 
:parison with death rates recorded elsewhere in cases 
of myocardial infarction on conventional therapy. If 
these 3 series are left out of table V. the amended 
figures read - 109 deaths in 694 cases treated with 
anticoagulants, giving a mortality rate of 15.9. 
The difference from the death rate in controls is 
still statistically significant. 
Such a reduction in mortality in treated cases 
in so significantly large a series is a very powerful 
argument for the effectiveness of anticoagulant 
therapy. However, a comparable reduction was achiev- 
:ed by simpler measures by Master and his associates 
(1936) over a decade ago. They treated 267 episodes 
of coronary thrombosis occurring in 243 patients by an 
800 caloric diet, prolonged bed rest and the avoidance 
of digitalis, adrenalin and nitrites. They recorded 
an all -over mortality rate of 16.5% and a mortality 
in first attacks of 80 only. The effectiveness of 
this form of management does not appear to have been 
confirmed/ 
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confirmed or disproved by other workers. à combina- 
:tion of Master's regime and anticoagulant therapy 
might well prove to be the most effective treatment 
of myocardial infarction. 
The incidences of thrombo -embolic complications 
recorded in the various anticoagulant treated series 
:and in control groups are noted in table VI. 
Table VI. Incidence of thrombo- embolic complications 
occurring in cases of myocardial infarction receiving 
',anticoagulant treatment and in control cases not so 
treated. 
uthors. 
Anticoagulant Control cases 
cases. 
Tv o . No. with tbrombo- No . No .with 
treated emboli. thrombi-emboli 
Nichol (1947 68 
Peters et al.(1946) 50 
Parker & Barker (1947) 50 










Glueck (1948) 44 3 44 12 
!McCall (1948) 71 2 - - 
Wright et al. (1948) 432 48* 368 92 
Totals 790 63 572 135 
I Incidence . 80 = 23.6' 
( 22 of these complications occurred in patients not 
under the influence of anticoagulants.) 
It is seen that thrombo- embolic processes com- 
:plicate myocaardial infarction very much less frequent- 
:ly when anticoagulants are administered. The 
difference in the figures recorded is statistically 
significant. If the cases in Wright's series which 
were not under the influence of anticoagulants when 
complications occurred, are omitted, the incidence in 
the/ 
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the anticoagulant group is 5.2. However, as Wright 
suggests, cols lications occurring in such circumstances, 
must be retarded as disadvantages inherent in anti - 
:coagulant therapy. Such complications are of course 
more common when dicumarol alone is used without heparin. 
There are less specific contra -indications to heparin 
and furthermore the tirombo- embolic processes which 
develop in the first three days of dicumarol therapy 
(in Wright's series they occurred in l.59ó of all cases 
in the treated group) would presumably be obviated by 
the simultaneous administration of heparin. If all 
observers had adopted the same strict criteria as 
Wright the incidence of thrombo- embolic complications 
recorded in their treated series would no doubt have 
been higher, but there is no reason to suppose that it 
would greatly have exceeded Wright's figure of 1190, a 
figure which is a marked and statistically significant 
improvement on the recorded incidence in the control 
group. 
xny critical assessment of the value of anti - 
:coagulant therapy must include a consideration of the 
frequency and severity of haemorrhagic manifestations 
in the series reported. These features are summarise 
in Table VII. 
Table VII. Incidence of mild and severe haemorrhagic 
manifestations occurring in cases of myocardial 
infarction under anticoagulant therapy. 
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Haemorrhagic manifestations giving rise to no 
great anxiety, such as microscopic haematuria, 
petechiae or epistaxis occurred in almost 6S of cases. 
Severe haemorrhages were very infrequent and there were 
no fatalities due to haemorrhage. All observers 
noted the effectiveness of intravenous Vitamin K. in 
.counteracting haemorrhages and raising prothrombin 
levels. In the light of these figures the small 
risJ_ of haemorrhagic manifestations cannot be consider 
:ed to contra- indicate the use of anticoagulants where 
the methods of laboratory control used in the above - 
mentioned series are available. It is worthy of no e 
that in all these series 3rothrombin time was estimat d 
by the method of (nick (1942) or a modification of it 
using acetone -extracted dried brain as the source of 
thromboplastin. There is now evidence that the use 
of Russell -viper venom as the source of thromboplastin, 
which is the common practice in Great Britain, is 
unsafe in the control of dicumarol therapy. 




The optimum prothrombin level in dicumarol 
therapy was considered to be 10 -30 or 20 -30 by all 
the authors reported above except Peters and his co- 
morkers. They elected to maintain a level of 35 -50. 
Their figures for rates of mortality and thrombo- 
embolic complications were lower than in any other 
series, which is very surprising if Wright's (1948) 
contention is correct that the few thrombo- embolic 
complications which do occur under dicumarol therapy 
happen when the prothrombin percentage is above 30, 
the upper limit of the therapeutic range. The most 
likely explanation is that Peters' criteria of assess- 
:ment of prothrombin percentage differed from those 
of other workers and that what he considered to be 
35 -50 prothrombin, others would have rated considerably 
lower. Peters used Brambel's (1945) modification of 
Quick's thromboplastic reagent and assessed prothrombin 
level on a different form of dilution curve from the 
standard one of Quick used by the other authors. The 
incidence of mild haemorrhages in Peters' series was 
the same as in the other reports which suggests that 
he achieved comparable prothrombin levels. 
Difficulty in maintaining prothrombin levels 
is considered in detail in only 2 of the series, those, 
of Parker & Barker and McCall. The former found that 
at some time the prothrombin level fell to dangerously 
low levels in 12 of their 50 cases and rose beyond the 
therapeutic range in 18. In McCall's 71 cases, 10 
were/ 
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were unduly slow to respond to dicumarol, in 4 cases 
the prothrornbin level fell too low and in 6 it rose 
too high at some period during the course of treatment 
It is likely that such difficulties occurred with 
similar frequency in the other series since methods 
of administration and control were similar. 
Whether combined heparin- dicumarol therapy is 
more effective than treatment by dicumarol alone 
'cannot be gleaned from these reports. Both modes 
of treatment were employed in the series of Parker 
¡and Barker and of Wright and his associates, but the 
results of each method were not separately assessed. 
Glueck treated all her cases by combined therapy and 
the mortality rate in her series, of 20 %0, was higher 
than that in any other series. However, the incidence 
of thrombo- embolic complications, of 6.0 was com- 
:parable to that in the whole group. Glueck's series, 
in point of fact, numbering only 44, was probably too. 
small to make comparison with the whole group valid. 
Wright's report of an incidence of thrombo -embolic 
complications in 1.5;6 of cases in the first 3 days of 
dicumarol therapy is a point in favour of heparin 
therapy. 
Reich & Eisenmenger suggest that anticoagulants 
will not prevent a second episode of coronary thrombosis. 
Parker & Barker reported 2 such episodes in their series 
of 50. However Wright's analysis of a much larger 
series indicates that anticoagulants are as effective 
in preventing such processes as they are "in respect of 
any/ 
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any other type of thrombo -embolic compir:ation. 
Most authors found daily estimations of pro - 
:thrombin time essential for control of dicumarol 
¡dosage but in the opinion of Peters and his associates 
and of Greisman &c Marcus adequate information can be 
obtained by estimating prothrombin every second day. 
The method of the majority appears preferable on the 
grounds of safety. 
Glueck continued dicumarol therapy for 21 days 
only, Wright urges administration for a minimum of 30 
days on the grounds that the risk of thrombo- embolic 
complications remains considerable for at least 4 
weeks. In Peters' series dicumarol was given for 42 
days. The comparatively small risk of thrombo -embolic 
processes in the 5th and 6th weeks hardly justifies 
the continued tenancy of a hospital b,ed.for such a 
purpose, provided the case is a straightforward one. 
The reports that have been published up to 
the present of the anticoagulant therapy of myocardial 
infarction in series of a significant size have been 
reviewed and summarised. It is difficult to escape 
the conclusion of Wright and his fellow- authors (1948) 
that the use of anticoagulants effects a striking 
improvement in the outlook of the patient suffering 
from myocardial infarction. It is noteworthy that 
all the reports are American. British observers 
'appear to have been as cautious in recognising the 
potential value of anticoagulants in myocardial 
infarction/ 
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infarction as they were three or four decades ago in 
accepting myocardial infarction as a clinical and 
pathological ,entity. In defence of British reluctan 
to accept without reserve the favourable conclusions 
of the american authors it is only fair to say that, 
though no large series, comparable to the merican 
ones, has appeared in the British literature, certain 
unfavourable experiences and impressions have been 
recorded. Peel (1947) reported the failure of 
dicumarol to prevent thrombo- embolic processes in 3 
cases of coronary thrombosis. He unfortunately does 
not clearly indicate the prothrombin level at which 
the complications occurred since he records the 
dicumarol effect in terms of the "prothrombin index ", 
and does not specify the method of prothrombin time 
estimation. Hill (1949) states that he has abandone 
the use of dicumarol in coronary thrombosis on accoun 
of its delayed and persistent action, the erratic 
nature of its effects and the difficulty in control 
should complications arise, but he thinks that the us 
of heparin is justifiable in cases of spreading 
thrombosis and in those cases in which the electro- 
:cardiogram is typical of massive through and through 
involvement. Evans (1948) in his recent text -book 
does not mention the use of anticoagulants in his 
account of the treatment of coronary thrombosis. He 
thinks the use of heparin is unjustified in cases of 
peripheral venous thrombosis because the risk of pul- 
monary embolism is small. 




though a very brief one, has recently appeared. 
Wood (1949) records 23 cases of cardiac infarct treate 
with dicumarol with 3 deaths - a mortality of 13. 
In 7 cases, however, of cardiac embolism complicated 
by pulmonary embolism there were 3 deaths also. 
Presumably these 7 were cases of coronary embolism 
complicating some other condition such as bacterial 
endocarditis and are therefore not really comparable to 
a general series of coronary thrombosis. 
In spite of the guarded or unfavourable opinions 
of British physicians, it is felt that the balance of 
evidence, particularly in view of the large and care - 
:fully controlled series reported by Wright and his 
associates, is strongly in favour of the real effect - 
:iveness of anticoagulant therapy in reducing mortality 
and morbidity from myocardial infarction. 
V. Clinical Study of hnticoagulant Therapy of 
Myocardial Infarction. 
(a) Plan of investigation, material studied and results. 
The material studied consists of the cases of 
coronary thrombosis with myocardial infarction ad- 
:mitted, from December 1947 to r'ebruary 1949, to a 
general medical unit, consisting of 34 male and 18 
female beds, in the Royal Infirmary of Edinburgh. 
The number of cases studied is too small to permit of 
any final conclusions as to the value of anticoagulant 
therapy in myocardial infarction but the experience 
gained/ 
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gained in the administration and control of anti - 
:coagulants has led to certain tentative conclusions 
and to the adoption of certain practical measures which 
my be of assistance to other workers in this field. 
To obtain a control series the documents of all 
cases of coronary thrombosis admitted to the same unit 
during the previous 5 years were carefully studied and 
analysed. That this is a highly unsatisfactory metho 
of achieving a control series is freely admitted, but 
admissions for coronary thrombosis were too infrequent 
to permit of division into "treated" and controls 
by treatment of alternate cases only. 
Only cases in which the diagnosis of coronary 
thrombosis was certain were included in eithereries. 
The diagnosis was based on an adequate combination of 
the accepted criteria, namely history of prolonged 
substernal pain with pallor, sweating, dyspnoea, 
flatulence, clinical findings of fall in blood pressure, 
tachycardia, occasional pericardial friction, slight 
pyrexia, leucocytosis and raised B.S.R. and typical 
electrocardiographic changes. Patients whose episode 
of myocardial infarction had occurred three weeks or 
more prior to admission were not included in either 
series. 
The original plan of the investigation was to 
administer dicumarol only to those patients who showed 
a clotting tendency in the blood, as evidenced by a 
definite reduction in the prothrornbin time of whole or 
diluted/ 
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diluted (25%) plasma. (Shapiro (1944) has reported 
that such a fall in prothrombin time is a premonitory 
sign of thrombo- embolisation. Peters and his 
associates (1946) adopted this plan, apparently 
successfully, in their study of the use of dicumarol 
in coronary thrombosis.) In cases which showed no 
clotting tendency initially, prothrombin time was 
estimated every 2nd day and if the tendency became 
'manifest, dicumarol therapy was started. In 3 of 
the first 8 cases studied, prothrombin times remained 
normal throughout the period in hospital, no thrombo- 
embolic complications occurred and recovery was satis- 
:factory. However it eventually became apparent that 
the onset of such complications could not always be 
forecast by changes in the prothrombin time as 
estimated by the method used in this study. In one 
case, a second coronary thrombosis developed on the 
11th day though the prothrombin time had been persist- 
ently normal since admission. A second case died 
within 24 hours of admission with a prothrombin time 
above normal. 
It was therefore decided to administer anti - 
:coagulants to all cases of established recent coronary 
thrombosis, without selection. Initially dicumarol 
alone was administered but when heparin became more 
readily available , combined heparin and dicumarol 
therapy was employed. In all, 15 cases were treated 
with anticoagulants, 6 with dicumarol alone, 6 with 
[combined/ 
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combined heparin and dicumarol and 3 with heparin alone 
because of impaired renal function. Treatment was 
otherwise conventional and was comparable in the two 
series, anticoagulant- treated and controls. 
The 2 series were not comparable in size and 
were found to be not strictly comparable in respect of 
age and sex. The average age in the anticoagulant 
series was 54.2 years and in the controls 59 years. 
There were 11 men and 4 women in the treated group as 
against 37 men and 7 women in the controls. It is 
impossible to state if the groups were comparable in 
severity but there was a similar incidence of previous 
history of angina of effort and /or coronary thrombosis 
the rate being 66% in the treated cases and 68& in the 
controls. 
Table VIII. compares the mortality rate and 
frequency of thrombo- embolic complications in the 2 
series. There may well have been more thrombo- 
ersbolic episodes in the control group than the number 
recorded. Special study of such complications was not 
being made at the time they were under treatment and 
events such as minor pulmonary emboli may well have 
wiled to be recorded. Examination of temperature 
charts reveals in some cases unexplained occasional 
elevations of temperature or pulse which may have been 
due to such'episodes. However, only thrombo- embolic 
complications noted in the case- records have been 
included in the number stated. 
Table VIII./ 
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Table VIII. Mortality rate and incidence of thrombo- 
embolic complications in cases of myocardial 
infarction treated by anticoagulants and in cases 









Deaths 1 6.6;v 13 29.5,6 
No. of cases with 
thrombo- embolic 
complications 1 6.6;0 11 25A 
No. of such 
complications. 1 6.6A 15 34A 
Statistical comparison is of course not 
warranted in such small and not strictly comparable 
series but it is seen that the figures quoted are in 
close accord with the findings of other workers in 
respect both of cases treated with anticoagulants 
(cf. Tables V. & VI.) and of cases receiving convention 
:al therapy only (cf. Tables IU, V. & VI.) The one death 
in the treated series occurred 32 hrs. after admission 
in a man of 75 who had sustained a coronary thrombosis 
10 days before. He was having repeated paroxysms of 
severe dyspnoea and cyanosis without pain. The heart 
was enlarged and there were moist sounds at the lung 
bases. Prothrombin time was normal but a heparin 
tolerance test revealed increased resistance to hepari 
Heparin was administered with satisfactory effect on 
the clotting time but the dyspnoeic attacks persisted 
and he died 24 hrs. after inauguration of heparin 
therapy. Pulmonary embolism had been thought likely 
lmt/ 
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but post mortem revealed extensive myocardial infarction 
of approximately 2 weeks duration and slight ante - 
mortem thrombosis within the left ventricle, but no 
'evidence of recent cardiac infarction or of'pulmonary 
embolism. The lungs and other viscera showed some 
venous congestion and there were small bilateral 
pleural effusions. These were not saneous, nor were 
there any other evidences of damage attributable to 
heparin. 
The one thrombo -embolic complication in the 
cases receiving anticoagulants was an episode of 
pulmonary infarction in a patient who had received 
1500 mg. of dicumarol in 8 days with no effect on an 
initially shortened prothrombin time. The episode 
was not severe and heparinisation was followed by 
uninterrupted recovery. 
In the control °oup the 15 thrombo- embolic 
processes that occurred in 11 cases were - 7 further 
attacks of coronary thrombosis, 5 pulmonary emboli, 
2 femoral emboli and 1 cerebral embolism. 
No cases of recent coronary thrombosis admitted 
during the period under review were intentionally 
omitted from the material studied but mention must be 
,made of 2 further cases which died within an hour or 
two of admission without a diagnosis having been made. 
One, a man of 67 was admitted unconscious and moribund 
with no details available of the history of the illnes 
He was thought to have had a cerebral vascular acciden 
but/ 
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but post -mortem revealed a massive recent anterior 
infarct. The second, a man of 56, was admitted with 
a complaint of a burning sensation in the throat and 
aching in both upper arms of 2 hrs. duration. Coronary 
thrombosis was considered a possibility but pulse and 
blood pressure were normal and there were no abnormal 
physical signs. sudden death occurred without warn- 
ing two hours after admission and post -mortem reveale. 
both old and recent myocardial infarcts. 
Including also the 4 cases (1 of them fatal) 
previously mentioned, which received no anticoagulants 
because no clotting tendency was demonstrable, it is 
seen that 21 cases of recent coronary thrombosis were 
admitted in the period under review and that there 
were 4 deaths. It is worthy of note that all 4 
occurred within 48 hours of admission. yicumarol 
therapy can of course have no effect on such fatalities 
and it is doubtful whether early heparinisation could 
an any way affect the issue, which appears to be 
determined by the massivity of the original infarct. 
In the control series only 2 of the 13 deaths occurred 
within 48 hrs. of admission. 
No severe haemorrhages due to heparin or 
dicumarol were encountered in this series and only 
one minor manifestation of dicumarol toxicity. One 
case with a prothrombin level of 15%, developed petechiae 
in the antecubital fossa and a tendency for blood to 




of dicumarol and administration of 
!vitamin K by mouth, gr.60 in 2 days, the prothrombin 
rose to 350 and the mild toxic manifestation cleared up. 
No conclusions as to the risks of dicumarol 
therapy are advanced from this small study. The 
reality of such risks was brought home by the observa- 
:tion of a moderately severe haemorrhagic manifestatio7 
of dicumarol toxicity which gave rise to some anxiety 
and led to a prolongation of hospitalisation in a case 
not in this series. A woman of 46 with periodic 
recurrent deep phlebothrombosis of both legs was 
admitted on account of recurrent pulmonary infarctions. 
Initial prothrombin time was normal and there was no 
evidence of any specific contra -indication to dicumarol 
therapy. 24 hrs. after an initial dose of 250 mg. 
of dicumarol there was no change in prothrombin level 
and a further dose of 200 mg. was administered. At 
48 hrs. prothrombin had fallen suddenly to 250 and no 
further dicumarol was/given. On the following day, 
with a prothrombin of 150 there was moderate vaginal 
haemorrhage and a large cutaneous ecchymosis with 
a subcutaneous haematoma appeared on one thigh. 60 m 
of a vitamin K analogue (Synkavit) and 0.25 Gm. of 
iaminophylline were administered intravenously. The 
'vaginal haemorrhage stopped within 12 hrs. and the 
following day prothrombin level had risen to 55. 
However, necrosis of skin and subcutaneous tissue took 
place at the site of the ecchymosis, with eventual 
sloughing and indolent ulceration which took 30 days 
to/ 
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to heal. Such a case must be regarded as a hyper- 
reactor to dicumarol and it is not apparent how such 
cases can be recognised and haemorrhagic manifestations 
avoided, on the methods of control used in this study, 
unless a smaller trial dose of dicumarol be given 
initially in all cases. This, of course, would 
inevitably lead to a much greater delay 
:auction of the anticoagulant effect of 
in the pro- 
dicumarol 
in the great majority of cases. The delay on 
standard dicumarol dosage is already a very considerable 
disadvantage and exhibition of an initial small trial 
dose cannot be recommended. 
Fortunately, judging from the extensive 
literature on dicumarol therapy and its toxic effects 
(vide p. 32 ) such unpredictable hyper -reaction to 
dicumarol appears to be rare and its small risk 
cannot be considered to represent a contra -indication 
to its use. 
It is not intended to append the case histories 
of the patients treated with anticoagulants but one 
case of some interest will be briefly described. 
In this patient, a man of 61, dicumarol was administezj- 
:ed for 83 days. This was the case, noted earlier, 
in whom a second episode of cardiac infarction occurred 
on the 11th day after admission though there had been 
no premonitory change in the prothrombin time. 
Dicumarol therapy was started immediately and a satis- 
:factory prothrombin deficiency obtained in 72 hrs. 
Dur ing, / 
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During the next 2 months the patient had repeated 
attacks of left ventricular failure characterised by 
pulmonary congestion, early pulmonary oedema and very 
marked Cheyne -Stokes respiration. In the apnoeic 
phases of the respiratory dysrhythmia, the patient 
became unconscious and the pulse imperceptible. 
ilminophyllin was found to have a dramatic effect on 
these attacks and mercurial diuretics were also 
administered with beneficial results for the pulmonary' 
congestion. On several occasions early right sided 
heart failure developed with venous filling in the 
neck, and slightly enlarged liver with a marked 
hepato- jugular reflux but with little or no dependent 
oedema. Digitalis was avoided for some time on 
account of its reported effect of increasing a clotting 
tendency but eventually it was administered and 
finally on a combination of digitalis aminophylline 
and mercurial diuretics the patient made a good 
recovery - so good that while at the Convalescent 
Home, he was able to walk to the top o the neighbour - 
:ing Corstorphine Hill without distress and without 
stopping en route: Dicumarol therapy was continued 
throughout this 22 month period because all the three 
drugs used in the treatment of the heart failure are 
reported to cause clotting tendency. If this is 
the case, dicumarol may be held to have played a 
prominent part in the successful outcome. 
(b)/ 
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(b) Dicumarol dosage and administration. 
Patients whom it was intended to treat by 
dicumarol were first assessed for the presence of any 
specific contra- indication, namely, haemorrhagic 
disease, liver disease, condition likely to cause 
hypoprothrombinaemia. or deficient renal function. 
Initial prothrombin time estimation was performed by 
the method considered in detail below. If the pro- 
:thrombin time was not significantly above normal and 
m.o contra- indication existed, dicumarol therapy was 
inaugurated with a dose of 300 mg. for patients over 
10 stone or 250 mg. for those under 10 stone. There - 
:after the prothrombin time was estimated daily and 
the daily dosage assessed on the prothrombin level. 
Assessment of prothrombin level was based on the rela -; 
:tion of the prothrombin time to a standard prothrombiñ 
dilution curve, the formulation and theoretical basis 
of which are considered below. The attempt was made 
to keep the prothrombin level at 300 or at least 
within the range of 20 -400. In only 2 cases did 
dicumarol cause a fall to the elected therapeutic 
range within 48 hrs., usually it took from 72 -96 hrs. 
Dicumarol was continued in daily dosage of 200 mg. 
until the level reached 500 and thereafter depending 
on speed of fall by 50 -100 mg. until 300 was reached. 
Qt 300 if the level was falling no further dicumarol 
was given, if stationary, 50 or 100 mg., depending 
upon the patient's assessed reaction to previous doses 
and, if rising, 50 -150 mg. depending on speed of rise 
and/ 
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;and patient's previous reaction. Even with this 
careful scheme of control, it was found to be extreme -f 
:ly difficult to keep prothrombin levels consistently 
within the elected therapeutic range and wide escape 
from this range occurred at some time or times in all 
12 cases studied. In one case 1500 mg. of dicumarol 
in 8 days caused no fall in the initially increased 
prothrombin level and pulmonary embolism developed. 
This case must be considered resistant to dicumarol - 
it may be of significance that he was found to have 
a raised blood cholesterol level of 270 mg.0. In 6 
'other cases, the prothrombin level rose to 600 or more 
at some point in the course of treatment, in 2 it fell 
to 120 and in 3 it escaped in each direction at 
different times to 600 or 150. In none of these 11 
cases was escape from the therapeutic range attended 
by any complication, whether of haemorrhage or throm- 
:bosis. The difficulty in maintaining the optimum 
prothrombin level is of course due to the fact that a 
dose of dicumarol does not affect the prothrombin 
level, as estimated by the method used in this study, 
for 48 -72 hours and that its effect lasts for a very 
variable period thereafter. In the 5 cases in which 
prothrombin fell to dangerously low levels, administra 
:tion of vitamin K was followed by a satisfactory rise 
in prothrombin. 60 mg. of Synkavit intravenously led 
to an appreciable rise in 6 hrs. in one case, but in 
another case a second similar injection 24 hrs. later 
was/ 
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was required before the prothrombin eventually rose to 
a safe level at 48 hours. In the other cases 40 mg. 
of Kapilon intramuscularly and 90 mg. of vitamin K 
¡orally proved effective. The intramuscular injection 
was found to be very painful. 
The length of the course of dicumarol administer - 
:ed to different patients varied, since the plan was 
to ensure an anticoagulant effect until the 28th day 
after the attack of coronary thrombosis. Depending 
on how long before admission the coronary thrombosis 
had occurred, dicumarol was administered for between 
16 -28 days, except in the one case already mentioned 
in which it was given for 83 days. 
As a further attempt at control of dicumarol 
dosage a simple blood clotting time (vide infra) was 
recorded at the same time as the prothrombin time. 
No direct correlation between the two was found. A 
fall of prothrombin level to 152,' or below was usually, 
but not invariably, associated with a prolongation of 
)'clotting time. In 2 cases a sudden increase in 
clotting time heralded a considerable fall in pro - 
:thrombin level 24 horns later. Such a rise in 
clotting time may be regarded as an indication for 
caution in dicumarol dosage. 
A careful watch was kept in each case for the 
appearance of haemorrhagic manifestations. The urine 
was examined microscopically daily but in no case did 
'haematuria occur. 
I J 
(c) Estimation of blood prothrombin level. 
It is clear from the preceding observations 
that dicumarol therapy demands regular accurate 
assessment of the blood protiirombin level. 
Prothrombin, the precursor of thrombin in the 
circulating blood, has, according to Astrup (1944), 
the physical and chemical attributes of a globulin 
but it is probably a complex of 2 or more components, 
including the factor 5 of Owren (1947) and Quick's 
labile factor- component A and stable factor -component 
B (Quick 1943 and 1947) . The first.2 factors named 
are probably identical. Dicumarol is known to act 
on component B. 
The exact amount of prothrombin in the blood 
is not known and it can only be approximately 
assessed as a percentage of normal by an estimation 
of its activity. Such an estimation depends upon 
a literal acceptance of the so- called classical 
theory of coagulation of Schmidt (1895) and 
Morawitz (1905). According to this theory 
coagulation depends upon the interaction of 4 factors, 
calcium, prothrombin, thrombokinase (vel thrombo- 
:plastin) and fibrinogen. If, experimentally, 
three of these factors are constant then it is 
considered that variations in the speed of 
coagulation must be proportional to variations in 
the concentration of the fourth in the mixture. 
This is the basis of the method of estimation of the 
blood/ 
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blood prothrombin level first devised and subsequently 
improved by Quick (1935 and 1942). In this method 
optimum amounts of thromboplastin and calcium are 
added to oxalated plasma and, since variations in 
fibrinogen in human plasma are not likely to be so 
wide as to introduce significant error, the clotting 
time recorded is taken to be inversely proportional 
to the concentration of prothrombin. 
In Quick's method a standardised preparation 
of acetone dried rabbit -brain is used as the source 
of thromboplastin. In order to assess the concen- 
:tration of prothrombin in a deficient plasma Quick 
formulated a dilution curve. The prothrombin times 
of serial dilutions of normal plasma in saline were 
estimated and plotted against the percentage dilutions 
of plasma which were held to be equivalent to the 
percentages of prothrombin. The prothrombin time 
of a prothrombin -deficient plasma could then be 
interpreted on this curve as indicating a certain 
prothrombin concentration. 
The method is open to several theoretical 
objections. The assumption that the rate of 
thrombin generation is proportional to the 
concentration of the interacting factors is not 
necessarily a valid one,and the method takes no 
account of the amount of thrombin produced but only 
the rate of production. The basis of the test is 
the classical theory that there are only 4 factors 
concerned/ 
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concerned in coagulation, which is now known to be 
untrue. Prothrombin itself probably has at least 
2 components, and accelerators and depressors of 
thrombin generation are known to be present in human 
plasma, variations in which may alter the results of 
the test. Furthermore dilution of plasma by saline 
reduces fibrinogen and other factors as well as 
prothrombin. 
Various methods have been devised to circum- 
:vent some of these difficulties, such as the 2- stage 
method of prothrombin determination based on the 
amount of thrombin produced (Warner et. al. 1936), 
and the dilution of plasma with prothrombin -free 
plasma or with fibrinogen, but these methods have 
their considerable difficulties of interpretation. 
Quick's method, in spite of the objections recorded, 
has proved its value and essential reliability in 
its application to a vast amount of clinical material. 
The procedure has been standardised and its 
reliability attested statistically by Aggeler and his 
associates (1946). It has stood the true test of 
time as a means of obtaining the information necessary 
for the control of dicumarol therapy, namely the 
range of prothrombin deficiency within which the 
patient is not liable to bleed or to suffer intra- 
:vascular complications. 
In this country the modification of Quick's 
method devised by Fullerton (1940) has been largely 
employe d/ 
78. 
employed. In this method, which was used in the 
present study, Russell viper venom takes the place of 
brain as the source of thrombokinase. Fullerton 
recommended the use of viper venom because of its 
ready availability as Stypven (B.W. & Co.) or Russven 
(Boots), its constant potency and its clarity in 
solution as contrasted with tissue extracts which 
require careful preparation and standardisation, 
gradually lose their potency and are milky in 
solution, making recognition of the end -point 
difficult. The technique of Fullerton's method, as 
employed in the present study, will be described in 
some detail. 
4.5 c.c. of the patient's venous blood are 
added to 0.5 c.c. of a 1.38% solution of sodium oxa- 
:late in a graduated centrifuge tube, thoroughly 
mixed and centrifuged at 5,000 revolutions for 5 
minutes. In a test -tube rack, standing in a water - 
bath with water at 38° C., are placed 10 standard 
size test -tubes (15 cm. X 1.5 cm.). In one of these, 
labelled calcium, are placed 2 or 3 c.c. of 40 molar 
solution of calcium chloride, in a second, labelled 
'kinase, 1 c.c. of a 
1 
solution of Russell viper 
10,000 
venom (the product of a standard pack of 0.1 mg. 
of Stypven) and in a third, labelled plasma, 1 or 2 
cc. of the supernatant plasma from the centrifuged 
specimen. A large boiling tube (20 c.m. x 3.5 c.m.) 
is/ 
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is immersed in the water -bath and three- quarters 
filled with the water at 3800. One of the empty 
standard -size test tubes is inserted for 4 of its 
5 
length through a perforated cork into the large 
boiling tube which is propped up in the water -bath. 
Appropriately labelled 0.2 cc. pipettes are placed in 
each of the 3 labelled tubes. 0.2 c.c. of plasma 
and 0.2 c.c. of 'kinase solution are accurately 
pipetted into the jacketed test -tube and gently 
shaken. 1 minute later 0.2 c.c. of the calcium 
solution is quickly added to this mixture and at the 
same time a stop -watch is started. The large tube 
holding the smaller reagent tube is quickly removed 
from the water -bath, held up between the observer's 
eye and an electric light and gently agitated with a 
rotatory motion. On the first appearance of fine 
opaque threads on the side of the inner -tube the 
watch is stopped and the time determined. Once 
experience in the method had been gained and the 
iecrumi que standardised it was found that repeated 
determinations on any plasma, the prothrombin time 
of which was normal or only moderately prolonged, did 
not vary by more than 1 -2 seconds. When the time 
was as long as 45 or 50 seconds there was sometimes 
a variation in succes -ive determinations of as much 
as 4-5 seconds. Such variations are not of 
significance as a study of the dilution curve (figure 
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II) will show. In practise the average of 2 
successive determinations was recorded as the 
prothrombin tins. 
Before prothrombin time estimations could be 
effectively employed in the control of dicumarol 
it was necessary to establish a prothrombin dilution 
curve for the particular technique employed. 
Prothrombin time determinations were carried out on 
serial dilutions in normal saline of the plasma of 
6 normal people. The results were comparable in 
the 6 and the dilution curve represented in figure 
II is formed from the average findings. It is seen 
that the relationship between prothrombin times in 
seconds and prothrombin percentage is not a recti- 
:linear one but in the form of a parabolic curve. 
Normal prothrombin time by this method was 
found to be 18 seconds, with a range of 16 -20 seconds. 
The prothrombin time of 25% diluted normal plasma 
was 33 seconds with a range of 29 -37 seconds. 
It is seen from figure II that the elected 
therapeutic range of 20 -40% prothrombin is equivalent 
to prothrombin times of 28 -38 seconds which therefore 
represent the range of prothrombin times aimed at 
under dicumarol therapy in the present study. In 
addition to the daily determination of the prothrom- 
:bin time of whole plasma in each patient, under 
dicumarol, the estimation was also performed on 25% 
diluted/ 
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diluted plasma in normal saline. The equivalent 
optimum range was found to be 65 -110 seconds. Escape 
from this range sometimes occurred 24 hrs. before 
escape from the therapeutic range was manifest in the 
prothrombin time of whole plasma. Some observers 
have recommended the use of diluted plasma only in 
dicnmtrol control as being a more sensitive index of 
prothrombin deficiency, (Link 1943 -4, Peters et al, 
1946). The author has found it a valuable ancillary 
aid in the control of dicumarol therapy and it adds 
little to the trouble of a prothrombin time 
estimation. Using the technique already outlined 
it was found that a satisfactory end -point was 
detectable in a determination carried out on a 25% 
dilution of a prothrombin- deficient plasma, but 
recognition of the end -point was difficult where only 
0.1 c.c. of the reagents was used and the reaction 
was observed in small tubes. 
Hobson and Witts (1941) recommended the 
addition of lecithin to Russell viper venom on the 
grounds that if the latter alone is used the coagu- 
:lation time may be affected by haemolysis, lipaemia, 
the number of platelets in vivo and in certain 
circumstances the speed and duration of centrifugal- 
isation and that, these inconsistencies are eliminated 
by the addition of lecithin. The prothrombin 
dilution curve resulting from the employment of the 
method/ 
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method of Hobson and Witts in a normal plasma is 
shown in figure III. It is seen that the therapeutic 
range of prothrombin time by this method, 11.5 -14.5 
seconds, is far too narrow for safety. It is 
concluded that the method is of no value in the control 
of dicumarol therapy. This has been amply confirmed 
by Biggs and Macfarlane (1949) who compared, both 
experimentally and clinically, the use in prothrombin 
time estimation of Russell viper venom with lecithin 
and brain thromboplastin. They conclude that the 
latter is satisfactory because it is able to predict 
a haemorrhagic level whereas with the former no 
certain haemorrhagic level can be predicted and the 
technique is dangerously insensitive to alterations 
in prothrombin concentration. 
What is more disquieting is that there is an 
increasing body of evidence that the use of Russell 
viper venom alone in prothrombin estimation is 
unsatisfactory and not without danger in the control 
of dicumarol therapy. Wright and Prandoni (1942) in 
one of the early clinical trials of dicumarol, used 
Russell viper venom and found it necessary to give 
much larger doses of dicumarol to achieve a reduction 
in prothrombin level than were advised by other 
workers using brain thromboplastin. The apparent 
fall in prothrombin level was often delayed for 8 -10 
days and 8 serious haemorrhages occurred in the first 
20/ 
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20 cases treated. Lempert (1948) found prothrombin 
levels, by Fullerton's method, of 35% and 25% in 2 
cases receiving dicumarol in whom Quick's method 
recorded 10% prothrombin. The most convincing 
evidence is that advanced by James (1949) . He was 
struck by the fact that in his cases under dicumarol 
therapy, whereas Quick's method afforded a critical 
prothrombin level of 10% above which bleeding rarely 
occurred, of a series of 30 controlled by the Russell 
viper venom method 7 bled with prothrombin levels of 
24-45%. He therefore performed both tests in a 
series of 20. He found that in every case on and 
after the 2nd day of dicumarol, the prothrombin 
level fell more rapidly as estimated by Quick's 
method than by Fullerton's and in every case, on 
stopping dicumarol, returned towards normal more 
rapidly as estimated by Quick's method (due allowance 
being made for the lower level to which it had 
fallen). He states that in view of the more rapid 
fall in prothrombin shown by the brain thromboplastin 
method, less dicumarol is required to keep the 
prothrombin within the therapeutic range of 10-30% 
and there is therefore less risk of haemorrhage. 
He thinks that the comparable safe range by the 
venom method might be 40-60% (which is difficult to 
maintain because of the narrowness of the equivalent 
prothrombin time range of 24 -28 seconds, as shown in 
figure/ 
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figure II) but that the venom method does not follow 
the true prothrombin level (or at least changes in 
blood coagulability) sufficiently closely to give 
warning of impending haemorrhage. He found that in 
some cases there is little prolongation even after 
haemorrhage has occurred. He concludes that for the 
safety of the patient and the peace of mind of the 
pathologist a return to Quick's method is long overdue. 
These observations afford some explanation of 
the difficulty experienced by the author in maintain- 
:ing the elected therapeutic range of prothrombin 
deficiency and it is suggested that the general use 
in Britain of the venom method is, to a considerable 
extent, responsible for the unfavourable experiences 
and impressions that have been recorded in this 
country and for the widespread reluctance to employ 
dicumarol as a therapeutic agent. It is felt that 
the conclusions of James are justified and that the 
general use in this country of brain thromboplastin 
for prothrombin estimations would be likely to lead 
to better results from dicumarol therapy and to a 
more favourable opinion of its value. 
It has been a common practice in this country 
to describe degrees of prothrombin deficiency in 
terms of the "prothrombin index" which is represented 
by the formula prothrombin time of control x 100. 
prothrombin time of patient 
This expression is an unhelpful one since the 
pro thrombin/ 
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prothrombin index of a prothrombin- deficient plasma 
bears no real relationship to the prothrombin 
concentration as indicated on a dilution curve. For 
instance by the method used in this study a prothrom- 
:bin index of 50% means a prothrombin concentration 
of 22% and an index of 33% is equivalent to a 
concentration of 12.5%. It is felt that this 
expression is misleading and its use should be 
abandoned. 
The method of application of dicumarol therapy 
employed in a small series of cases of myocardial 
infarction has been described in detail. The 
theoretical and practical aspects of the estimation 
of degrees of prothrombin deficiency have been 
considered. The difficulty of maintaining pro - 
:thrombin concentrations within an elected therapeutic 
range when prothrombin is estimated by the venom 
method has been recorded in this small series and it 
has been noted that assistance in dicumarol control 
may be obtained by estimation of simple blood 
clotting time and estimation of prothrombin time of 
25% plasma in addition to that of whole plasma. 
Evidence has been presented from the literature for 
the belief that the use of brain thromboplastin in 
prothrombin estimation affords a safer and more 
efficient means of control of dicumarol therapy than 
the use of Russell viper venom. It is concluded that 
the use of brain thromboplastin is the method of choice. 
!Addendum to estimation of blood prothrombin level. 
The possibility of variations in the potency of 
the thromboplastin used and the likelihood of slight 
variations in the observers technique make it 
necessary to determine the prothrombin time of a 
normal control at the same time as the estimation is 
performed on the patient's blood. In the author's 
experience such variations have not occurred with 
Stypven (B.W. & Co.) but have been observed with 
Russven (Boots). Page and de Beer (1943) have 
shown that the potency of Stypven is uniform within 
and between batches and that it is stable for at 
least 5 years. 
Determination of prothrombin time by a 
capillary blood method, such as that of Innes and 
Davidson (1941), is not recommended. As the 
authors point out the results vary considerably 
with the temperature of the ward and can only be 
expressed in terms of the prothrombin index. The 
method is not sufficiently precise for control of 
dicumarol therapy. 
86. 
(d) Heparin. Administration and Control. 
Heparin has been administered in this series, 
in the latter part of the period under review, to 
all cases of recent myocardial infarction because, 
as has been already recorded, it has been felt that 
there is a real danger of thrombo- embolisation in the 
few days before dicumarol takes effect (1.5% of cases 
in Wright's (1948) series) and because heparin might 
possibly have some effect on the primary thrombus. 
As soon as the diagnosis has been made a 
heparin tolerance test, the technique of which is 
detailed below, has been performed chiefly from the 
point of view of interest but also because this test 
gives some indication of the dosage of heparin 
required. Heparin has then been administered 
intravenously in a usual initial dosage of 12,500 
units followed by 7,500 to 10,000 units 6- hourly. 
The preparation used in all cases has been Liquemin 
(Roche). Dosage required has been controlled by the 
daily estimation of the blood clotting time. The 
estimation has been carried out each day at a time 
approximately 4 hours after an injection of heparin. 
It has been found that the clotting time tends to 
become increasingly prolonged on successive days and 
the dosage of heparin has been adjusted to ensure 
that the daily clotting time has been approximately 
20 minutes. Excessive prolongation to the point of 
apparent incoagulability has been recorded in a few 
instances/ 
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instances with no ill effect. 
Heparin has been continued until dicumarol 
has been shown to have taken effect by a significant 
lowering of the prothrombin level. This estimation 
is performed daily at a point of time at least 4 
hours after an injection of heparin, since it is 
known that a single injection of heparin itself 
causes an increase in prothrombin time which is 
marked for 1 hour and does not finally return to 
normal for 3 hours (Long et al. 1946). 
It has been found possible to abolish the 
inconvenience of repeated venepuncture by the use of 
an indwelling needle with a special attachment or by 
the use of indwelling polythene tubing. The special 
attachment consists of a record fitting mount with 
a small hollow screw cap containing a replaceable 
rubber diaphragm. This has been specially made for 
the purpose by Archd. Young and Sons Ltd., Edinburgh. 
A vein on a flat surface of the forearm is chosen 
and, with strict sterile precautions, a needle of 
appropriate size to serve as an indwelling needle 
(B.W.G. 18 or 20 are suitable) is inserted into the 
vein and the dose of heparin given. The special 
attachment, having been previously assembled and 
filled with heparin (it requires only a fraction of 
a c.c.) is attached to the needle and the whole 
strapped down to the forearm and covered with a 
sterile/ 
Introducing Needle. "B" 
Rubber Diaphragms. "E" 
tolythene Tubing, "A" 
Needle to fit into 
Polythene Tubing. 
Adaptor to hold Rubber 
Diaphragm,, (Record Fitting). 
"D" 
uC" 
PLATE I. Apparatus for intravenous administration 
of heparin, designed to avoid the need for 
repeated venepuncture. (vide p. 88). 
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sterile dressing. It is recommended that the small 
venepuncture wound be sealed with collodion. 
Succeeding injections are given by the nursing staff 
by inserting a fine hypodermic needle, with due 
aseptic precautions, through the rubber diaphragm. 
It is possible to administer heparin quite success - 
:fully by this method for several days without a 
change of needle. The method has been employed for 
as long as 10 days on one needle without discomfort 
to the patient. 
The use of indwelling polythene tubing has 
been found more generally useful as it can be 
inserted at the antecubital fossa where veins are 
more easily found and it allows the patient to move 
his arm more freely than is the case with the use of 
an indwelling needle. The tubing used has been the 
polythene cannula, size 1 (bore 0.5 m.m.) of Allen 
and Hanbury. It has been found that this tubing 
can usually be threaded through a needle of bore 
B.W.G. 14 but occasionally, owing to slight 
variations in the diameter of the tube, a B.W.G. 12 
needle may be required. Some 20 c.m. of the tubing, 
having been found to slip easily through the chosen 
introducing needle, are sterilised by boiling for 15 
minutes. The special attachment noted above is 
filled with heparin and attached to a hypodermic 
needle of such diameter that it is held firmly when 
inserted/ 
PLATE II. Intravenous polythene tubing in use. 
The skin has been painted with iodine to 
demonstrate the cannula more clearly. For 
the same reason the latter has been left 
longer than is necessary. It is essential 
to strap the cannula firmly to the skin or 
it may disappear into the vein. At the time 
of the photograph, the apparatus had been in 
satisfactory use for 5 days and there was no 
reaction in skin or vein. 
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inserted into the tubing (15 S.W.G. is usually 
satisfactory). The tubing is filled with heparin 
and the initial dose of heparin then injected into 
the chosen vein by means of a syringe and the chosen 
introducing needle. The syringe is removed, the 
polythene tubing threaded through for 10 -12 cm. into 
the vein, the introducing needle withdrawn from the 
vein and quickly slipped off the tubing and the 
hypodermic needle with the special attachment quickly 
inserted into the free end of the polythene cannula. 
The whole is then strapped down and covered with a 
sterile dressing. Succeeding heparin injections are 
then given as before by insertion of a fine hypodermic 
needle through the rubber diaphragm. 
Serial clotting times have shown that the 
polythene tubing does not impair the anticoagulant 
effect of heparin. The use of this simple device 
has been appreciated both by patients and resident 
medical staff in its obviation of the need for 
repeated venepuncture. 
No serious toxic effects from heparin have 
been noted but transitory side effects have been 
observed on several occasions. 1 patient with 
coronary thrombosis on whom daily heparin tolerance 
tests were being performed had a short -lived but 
alarming anaphylactoid crisis. Within 45 seconds of 
an intravenous injection of 2,500 units of heparin 
(the/ 
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(the fifth he had received in 5 days) he became 
suddenly unconscious with laryngeal spasm, cyanosis, 
tonic spasm of limbs and tachycardia. The laryngeal 
spasm and cyanosis passed off in 30 seconds and 
consciousness returned in 1 minute. The tachycardia 
settled down within a few minutes and the patient 
felt quite well. No further heparin was given. 
Another patient, with pulmonary infarction, within 2 
minutes of an intravenous injection of 10,000 units 
of heparin, developed tinnitus, vertigo, lacrimation, 
diplopia and a fluttering sensation in the chest 
lasting for over 1 hour. Similar but milder 
symptoms followed injection of 1000 units of heparin 
7 hours later. Other patients who received heparin 
from the same phials as in both of these cases were 
unaffected. In the second case, a 2nd course of 
heparin was administered, after a cautious trial 
dose, some 12 days later without any side -effects. 
The most likely explanation of these toxic 
manifestations would appear to be the presence of 
some impurities in the batch of heparin to which the 
patients had become sensitised. 
2 cases of coronary thrombosis complained of 
pain in the chest 2 an hour or so after an injection 
of heparin. In one the pain was a dragging 
sensation across the right lower ribs lasting for 
about an hour and accompanied by slight general 
malaise/ 
91. 
malaise. In the second there was pain across the 
left chest passing up to the shoulder and associated 
with frontal headache. The possibility of a 
further episode of cardiac infarction was considered 
but there was no other evidence of this, clinical or 
electrocardiographic and recovery thereafter was 
uneventful. 
3 patients with coronary thrombosis who were 
complaining of some substernal pain at the time of 
the initial injection of heparin stated that the pain 
was relieved. No conclusion is advanced from this 
since all were no doubt expecting some relief from an 
injection but it is worthy of note that relief, 
following heparin, of pain associated with vascular 
occlusion has been reported by other observers, in 
peripheral arterial embolism by Burt (1947) and in 
coronary thrombosis by Glueck and her associates 
(1948). 
Clotting Time Estimation. 
The clotting time was simply estimated by 
inverting every 2 minute a 10 x 75 m m. glass tube 
containing 1 c.c. of the patient's venous blood and 
noting the time of coagulation. Control of heparin 
therapy does not appear to require a very accurate 
assessment of the clotting time and the capillary 
tube method is probably just as satisfactory. 
Heparin Tolerance Test. 
Hagedorn/ 
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Hagedorn and Barker (1948) studied the response 
of subjects with and without intravascular thrombosis 
to an intravenous injection of 25 mg. (= 2,500 units) 
of heparin. They estimated the clotting time by 
the simple method described above at 10 minute 
intervals for 80 minutes following the injection and 
found that in every case the maximum prolongation 
occurred at 10 mins. They found that the response 
in normal subjects does not vary from day to day but 
that it varies considerably in different persons 
suffering from the same disease. They studied 50 
normal subjects and 70 patients with and without 
intravascular thrombosis and classified the material 
studied in 4 arbitrary grades according to the length 
of the 10 minute clotting times. In grade I, 
described as hyper- reactors, the clotting time 10 
minutes after I.V. injection of 25 mg. of heparin was 
90 minutes or more, in grade II, the normals, 40 -90 
minutes, in grade III, the hypo- reactors, 10 -40 
minutes and in grade IV, the non -reactors, less than 
10 minutes. The authors found that of 50 normal 
subjects, 47 were in the normal grade, 2 were hyper - 
reactors and 1 a hypo- reactor. Whereas of 61 
subjects with evidence of intra- vascular thrombosis, 
19 were normals, 18 hypo -reactors and 24 non -reactors. 
This test has been performed in 8 cases of 
coronary thrombosis in the present study; of these 
1/ 
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1 was in the normal grade, 5 were hypo- reactors and 
2 non -reactors. It is seen that 7 out of 8 cases 
of coronary thrombosis showed increased resistance 
to heparin, suggesting an upset in the coagulation 
system of the blood with a tendency towards clotting. 
Heparin (in vitro) Clotting Time Estimation. 
The fact that one of the actions of heparin 
is to neutralise prothrombin and the fact that its 
anticoagulant action is quantitative has suggested 
that increasing degrees of prothrombin deficiency 
in a patient's blood may be associated with increas- 
:ing sensitivity to heparin in vitro. To test this 
hypothesis a simple manoeuvre, named by the author 
for convenience the heparin clotting test, has been 
employed. In this test a fixed amount of venous 
blood from the patient is added to a 10 x 75 mm. 
glass tube containing a fixed minute quantity of 
heparin (2 c.c. of blood to 0.5 units of heparin in 
0.1 c.c. water has proved most satisfactory) and the 
clotting time determined in the usual way. 
Investigation is at present being carried out to 
elucidate whether the prolongation of the heparin 
clotting time of a prothrombin- deficient plasma 
(which has been shown to exist) is proportional to 
the degree of prothrombin deficiency as determined 
by estimation of the prothrombin time. Preliminary 
results suggest that in any one individual such a 
correlation/ 
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correlation does exist but that there is a fairly 
wide variation in the heparin clotting times recorded 
in different individuals who have the same prothrombin 
percentage. 
This test when properly standardised and 
evaluated may prove of assistance in the control of 
dicumarol therapy but results so far suggest that it 
is very unlikely to obviate the need for prothrombin 
estimations. 
The method,X of administration and control of 
heparin therapy employed in a small series of cases 
of coronary thrombosis and other thrombotic 
conditions has been considered. Toxic reactions 
have been recorded in a small number but judging from 
their short -lived nature and their infrequency as 
reported in the literature they do not appear to 
constitute a bar to the use of heparin. The 
technique of a heparin tolerance test and a so- called 
heparin clotting test and their application have 
been briefly described. 
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VI. Vitamin K Therapy of Myocardial Infarction. 
Preceding sections have revealed a widespread 
recognition of the frequency of thrombo- embolic 
complications in myocardial infarction and of the 
theoretical justification for and practical 
effectiveness of measures designed to abolish intra- 
:vascular clotting by lowering the blood prothrombin 
level. It is therefore all the more surprising to 
find it recorded that acute coronary occlusion is 
invariably associated with hypoprothrombinaemia and 
that large doses of vitamin K are an effective form 
of therapy. 
An earlier report of Doles (1943) was 
considered in part II of this paper but more recently 
(Doles 1947) he has published a study of the prothrom- 
:bin levels in 64 cases of acute coronary occlusion 
and of their treatment by large intravenous or intra- 
:muscular doses of vitamin K. He found that in all 
cases there was a marked fall in prothrombin level 
from 5 to 24 hours after the incident of occlusion, 
the average level reached being 55iß. He treated his 
cases with 50 -72 mg. of vitamin K every 6 -8 hours 
until the prothrombin was 100%. He states that 
relief of pain followed an injection of vitamin K 
within 2 -3 hours, though mild discomfort sometimes 
lasted for 24 hours. The blood pressure was restored 
to normal levels usually by the 2nd day but at times 
not/ 
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not until the 5th day and thereafter it maintained its 
original level unless there was a recurrence of 
hypoprothrombinaemia. He states that none of the 
fully treated cases could be classified as sick after 
the 3rd day. There were 11 deaths in his series of 
64 (a mortality rate of 17.2 %) but he states that 
only 55 of these cases were fully treated and of 
these only 2 died (a mortality of 3.6%). 
Doles thinks that haemorrhage into the wall of 
the coronary artery is the precipitating cause of an 
incident of coronary thrombosis and that such haemorr- 
:hages are due to the hypoprothrombinaemia associated 
with an underlying deficiency of vitamin K. 
Findings so diametrically opposed to those of 
a host of other workers require some explanation. 
Critical consideration of the paper of Doles reveals 
certain points that are worthy of comment. Doles 
estimates prothrombin levels by the bedside technique 
of Ziffren and his associates (1940) in which 1 c.c. 
of the patient's whole blood is added to 0.1 c.c. of 
thromboplastin and the time of coagulation determined. 
The results are expressed in terms of the prothrombin 
index (vide p. 84) . Such a method of prothrombin 
estimation has nothing to recommend it, save the 
dubious merit of simplicity. It has been found to 
be completely unreliable, for instance, in control of 
dicumarol therapy as an index of degrees of prothrom, 
:bin/ 
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:bin deficiency. The use of this method in itself 
largely invalidates Doles' conclusions. However it 
may be objected that the results in his fully treated 
cases are a good proof of the soundness of the 
rationale and the form of therapy adopted. On the 
other hand the reliability of his figures is open to 
suspicion. He does not state on what criteria a 
diagnosis of acute coronary occlusion was based. 
His statement that the blood pressure returned to 
normal within 24 hours or at the longest 5 days after 
the occlusive episode in all cases suggests that the 
attacks were very mild or indeed may not have been 
episodes of cardiac infarction at all. For Master 
and his associates (1943) have shown that in the 
majority of cases of coronary occlusion the blood 
pressure does not return to its original level for 
at least 3 to 4 weeks. It can hardly be supposed 
that vitamin K therapy, even if it is effective in 
controlling intimai haemorrhage in the coronary 
artery, can so radically alter the normal march of 
events in myocardial infarction as to effect a rapid 
and permanent return of the blood pressure to normal 
and Doles agrees that his treatment can have no 
effect on the repair of an infarct once it has formed. 
Furthermore his contention that haemorrhage into the 
coronary vessel wall is the precipitating cause of 
coronary thrombosis has been disproved by English and 
Willius/ 
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Willius (1943) who have shown in convincing 
pathological studies that such haemorrhage plays a 
major role in very few instances. 
If the theories of Doles were correct, 
dicumarol therapy should lead to intimal haemorrhages 
and further episodes of coronary thrombosis. A 
wealth of inescapable evidence to the contrary, 
experimental, pathological and clinical, has already 
been presented and need not be repeated. His 
experiences have not been confirmed by any other 
workers and he produces no experimental and very 
little pathological supportive evidence. It is 
concluded that his paper will not stand up to critical 
analysis. His fundamental hypothesis is unsound, 
his methods unreliable, his clinical data lack 
conviction and his conclusions cannot be justified. 
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VII. Discussion. 
The great therapeutic advances of the last 
decade, notably in the control of bacterial 
infections, have, by increasing the span of life and 
also by inviting comparison with their own effective- 
ness, thrown into high relief the meagre progress 
that has been achieved in resisting the onslaught of 
certain other diseases. It is generally agreed 
that the incidence of coronary thrombosis is 
progressively increasing but 20 -30 years of steady 
improvement in diagnosis and clinical and 
pathological definition had brought about little 
improvement in mortality rate apart from that due to 
earlier recognition. The challenge to organised 
medicine constituted by the increasing frequency of 
this condition is strikingly exemplified by the 
carefully calculated conclusion of blaster (1947) 
that every year in the U.S.A. at least 1 in in 50, 
40 years of age and over, sustains closure of a 
coronary artery. Until more is known about the 
aetiology of athero- sclerosis in man, prevention of 
coronary thrombosis will remain a problem; but the 
material presented in this paper has shown that in 
treatment the results achieved on conventional 
measures can be materially improved by a mode of 
therapy which is based on sound pathological and 
pharmacological grounds. Furthermore, for the 
application/ 
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application of this therapy to coronary thrombosis 
and its attendant thrombo- embolic complications 
there is an excellent precedent in its successful 
application to other forms of intravascular thrombosis. 
The pathological justification for this 
anticoagulant therapy has been attested in a review 
of the literature which has shown that thrombo- 
embolic complications are a very real danger in cases 
of cardiac infarction and that they contribute 
significantly both to mortality and to subsequent 
invalidism following such cardiac episodes. The 
possibility of a fundamental disorder of the 
coagulation system of the blood, with a tendency 
towards clotting, as the cause both of the coronary 
thrombosis and of the complicating thrombo-embolic 
processes has been considered. Gibson's (1949) 
revolutionary theory that such a clotting tendency 
is responsible also for the underlying atherosclerosis, 
is, it seems to the author, open to an attempt at 
experimental verification in animals. Leary (1941) 
has shown that high cholesterol feeding will produce 
typical atherosclerosis in rabbits and Link (1943 -4) 
has recorded that effective lowering of the prothrom- 
:bin level in rabbits results from dicumarol 
administration. If, in a suitably designed 
experiment, it can be shown that dicumarolisation 
will prevent such experimental atherosclerosis it 
would/ 
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would constitute strong support for Gib son's theory. 
The converse theory that a form of 
haemorrhagic diathesis is ultimately responsible for 
the development of coronary thrombosis has been 
critically assessed and is considered, based as it is 
on a pathological misinterpretation and on unsound 
biochemical methods to lack validity. 
The established effectiveness of heparin and 
dicumarol in the prophylaxis and treatment of 
intravascular thrombosis both in experimental animals 
and in man has led to the acceptance of two 
verities; firstly, substantial impairment of the 
ability of the blood to coagulate, can exist without 
harmful effects if it is carefully controlled, and 
secondly, such impairment will largely prevent 
intravascular thrombosis, and combat it when it has 
already developed. These established facts form 
the pharmacological justification for the use of 
anticoagulants in coronary thrombosis. 
It is clear that both heparin and dicumarol 
have their considerable disadvantages. Their use 
must be considered the first step towards securing 
an entirely satisfactory anticoagulant for clinical 
use. The ideal anticoagulant should possess the 
following characteristics: (1) Effectiveness of 
oral administration (2) Cheapness (3) Approximate 
predictability of effect of a specified dose 
(4)/ 
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(4) Ease of control by a simple safe and rapid method 
which can be performed by the relatively unskilled. 
(5) Lack of dangerous toxic effects when administered 
for short or long periods (6) Control of Over - 
:activity by a rapidly -acting antidote. 
Though both anticoagulants at present 
available are far removed from the ideal, their 
application to coronary thrombosis and the 
statistically significant reduction in mortality and 
thrombo -embolic complications effected in numbers as 
large as those summarised in Tables V and VI, are 
highly convincing evidence of their value. The 
figures quoted largely refer to the use of dicumarol 
alone and the value of heparin in coronary 
thrombosis does not rest on such firm statistical 
grounds, since its reported use has been more limited. 
However, since it has been shown experimentally and 
clinically to be probably more effective and 
certainly less dangerous than dicumarol, there is no 
reason to suppose that heparin would be less effective 
than dicumarol were it feasible to administer it 
throughout the period of risk of thrombo -embolisation. 
It is the author's opinion, for reasons already 
given (p. 36 and 86) that a combination of heparin 
and dicumarol is likely to prove the most effective 
therapy. 
Evidence has been presented for the belief 
that/ 
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that dicumarol administration is controlled most 
safely and effectively by Quick's method of 
prothrombin estimation. Tulloch (1949, personal 
communication) from a wider experience of dicumarol 
therapy has confirmed the author's belief that it 
is difficult to maintain a therapeutic range of 
prothrombin deficiency when blood prothrombin is 
estimated by the Russell viper venom method. Quick 
(1947) has stated that unwarranted modifications of 
his procedure have contributed nothing to increasing 
its simplicity, accuracy or practicability. He 
maintains that the correct technique for his method 
can be acquired by any competent technologist in one 
or two hours and that an additional hour is 
sufficient to learn the procedure for preparing 
thromboplastin from rabbit brain. The author has 
suggested that the general use in Britain of the 
venom method is largely responsible for the guarded 
or unfavourable opinions of dicumarol therapy that 
are current in this country. It is recommended that 
in British hospitals, the pathologist should accept 
the responsibility for determining prothrombin levels 
by Quick's method. This, it is felt, would lead to 
a more widespread, a safer and a more effective use 
of dicumarol and to a truer appreciation of its 
value. 
The substance of this paper has shown firstly, 
that/ 
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that the rationale of anticoagulant therapy in 
coronary thrombosis with myocardial infarction is 
sound and secondly, that the death rate and incidence 
of thrombo- embolic complications in patients receiv- 
:ing such additional therapy are markedly lower than 
those experienced by patients solely treated by 
conventional methods. It is the considered opinion 
of the author that, in the absence of any specific 
contra -indication and provided there are facilities 
for the daily estimation of prothrombin time by 
Quick's method, combined heparin and dicumarol 
therapy should be applied to all cases of coronary 
thrombosis with myocardial infarction. The more 
widespread use of this potent therapeutic weapon will 
effect significant inroads into the ravages of a 
disease which is now steadily gaining ground. 
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VIII. Summary. 
1. The reported incidence of coronary thrombosis 
is increasing and with lengthening of the span 
of life and ageing of the population will 
probably continue to increase. 
2. Thrombo -embolic complications contribute 
significantly to the mortality from and invalidism 
following episodes of myocardial infarction. 
3. A fundamental upset of the coagulation system 
appears probable in cases of coronary thrombosis. 
Further investigation is indicated to confirm 
this clotting tendency and to elucidate its 
cause. 
4. The anticoagulants, heparin and dicumarol, are 
effective, experimentally and clinically, in the 
prophylaxis and treatment of intravascular 
thrombosis and embolism. 
5. In 905 cases of myocardial infarction treated 
with anticoagulants the death rate was 14.1ÿo as 
compared with a death rate of 27.3ìo in 572 
similar cases receiving conventional therapy only. 
6. Thrombo- embolic complications occurred in 8 
of 805 cases of myocardial infarction receiving 




7. In 813 cases of myocardial infarction treated 
with anticoagulants there were minor haemorrba gic 
manifestations in 47, severe haemorrhages in 2 
and no fatalities attributable to the anti - 
:coagulants. 
8. Regular, preferably daily, estimations of 
prothrombin time are essential for the control of 
dicumarol therapy and Quick's is the method of 
choice. It is suggested that the general use in 
this country of the Russell viper venom method is 
responsible for current unfavourable impressions 
of dicumarol therapy. 
9. In the absence of specific contraindications 
and provided there are adequate laboratory 
facilities combined heparin- dicumarol therapy 
should be applied in the author's opinion, to all 
cases of coronary thrombosis with myocardial 
infarction. 
10. Simple methods of avoiding the inconvenience, 
in heparin therapy, of repeated venepuncture have 
been described. 
11. Both heparin and dicumarol have considerable 
disadvantages. Vigorous search should be made 
for an anticoagulant which is entirely 
satisfactory in clinical use. 
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